Recognition	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
tegument	I-protein
proteins	I-protein
by	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O

The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O

The	O
antiviral	O
functions	O
of	O
infiltrating	B-cell_type
CD4-bearing	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	B-protein
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O

The	O
antigens	O
recognized	O
by	O
many	O
HSV-specific	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O

T	B-cell_type
cells	I-cell_type
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	B-DNA
DNA	I-DNA
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O

Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	B-protein
protein	I-protein
VP22	B-protein
and	O
the	O
viral	B-protein
dUTPase	I-protein
,	O
encoded	O
by	O
genes	B-DNA
UL49	I-DNA
and	I-DNA
UL50	I-DNA
,	O
respectively	O
,	O
are	O
T-cell	B-protein
antigens	I-protein
.	O

Separate	O
epitopes	B-protein
in	O
VP22	B-protein
were	O
defined	O
for	O
T-cell	B-cell_line
clones	I-cell_line
from	O
each	O
of	O
three	O
patients	O
.	O

Reactivity	O
with	O
the	O
tegument	B-protein
protein	I-protein
encoded	O
by	O
UL21	B-DNA
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O

Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	B-protein
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
VP22	B-protein
.	O

Some	O
tegument-specific	B-cell_line
CD4	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
exhibited	O
cytotoxic	O
activity	O
against	O
HSV-infected	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O

JOURNAL	NULL
OF	NULL
ViRoLOGY	NULL
,	NULL
Sept.	NULL
1998	NULL
,	NULL
p.	NULL
7476-7483	NULL
0022-538	NULL
Vol	NULL
.	NULL

72	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Copyright	NULL
©	NULL
1998	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Recognition	NULL
of	NULL
Herpes	NULL
Simplex	NULL
Virus	NULL
Type	NULL
2	NULL
Tegument	NULL
Proteins	NULL
by	NULL
CD4	NULL
T	NULL
Cells	NULL
Infiltrating	NULL
Human	NULL
Genital	NULL
Herpes	NULL
Lesions	NULL
DAVID	NULL
M.	NULL
KOELLE	NULL
,	NULL
!	NULL

>	NULL
*	NULL
JEANNINE	NULL
M.	NULL
FRANK	NULL
,	NULL
*	NULL
``	NULL
``	NULL
MATTHEW	NULL
L.	NULL
JOHNSON	NULL
,	NULL
``	NULL
anp	NULL
WILLIAM	NULL
W.	NULL
KWOK*	NULL
Department	NULL
of	NULL
Medicine	NULL
``	NULL
and	NULL
Department	NULL
of	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
``	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98105	NULL
;	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98104	NULL
``	NULL
;	NULL
and	NULL
Virginia	NULL
Mason	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98101°	NULL
Received	NULL
16	NULL
March	NULL
1998/Accepted	NULL
19	NULL
May	NULL
1998	NULL
The	NULL
local	NULL
cellular	NULL
immune	NULL
response	NULL
to	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
is	NULL
important	NULL
in	NULL
the	NULL
control	NULL
of	NULL
recurrent	NULL
HSV	NULL
infection	NULL
.	NULL

The	NULL
antiviral	NULL
functions	NULL
of	NULL
infiltrating	NULL
CD4-bearing	NULL
T	NULL
cells	NULL
may	NULL
include	NULL
cytotoxicity	NULL
,	NULL
inhibition	NULL
of	NULL
viral	NULL
growth	NULL
,	NULL
lymphokine	NULL
secretion	NULL
,	NULL
and	NULL
support	NULL
of	NULL
humoral	NULL
and	NULL
CD8	NULL
responses	NULL
.	NULL

The	NULL
antigens	NULL
recognized	NULL
by	NULL
many	NULL
HSV-specific	NULL
CD4	NULL
T	NULL
cells	NULL
localizing	NULL
to	NULL
genital	NULL
HSV-2	NULL
lesions	NULL
are	NULL
unknown	NULL
.	NULL

T	NULL
cells	NULL
recognizing	NULL
antigens	NULL
encoded	NULL
within	NULL
map	NULL
units	NULL
0.67	NULL
to	NULL
0.73	NULL
of	NULL
HSV	NULL
DNA	NULL
are	NULL
frequently	NULL
recovered	NULL
from	NULL
herpetic	NULL
lesions	NULL
.	NULL

Expression	NULL
cloning	NULL
with	NULL
this	NULL
region	NULL
of	NULL
DNA	NULL
now	NULL
shows	NULL
that	NULL
tegument	NULL
protein	NULL
VP22	NULL
and	NULL
the	NULL
viral	NULL
dUTPase	NULL
,	NULL
encoded	NULL
by	NULL
genes	NULL
U	NULL
,	NULL
49	NULL
and	NULL
U	NULL
,	NULL
50	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
T-cell	NULL
antigens	NULL
.	NULL

Separate	NULL
epitopes	NULL
in	NULL
VP22	NULL
were	NULL
defined	NULL
for	NULL
T-cell	NULL
clones	NULL
from	NULL
each	NULL
of	NULL
three	NULL
patients	NULL
.	NULL

Reactivity	NULL
with	NULL
the	NULL
tegument	NULL
protein	NULL
encoded	NULL
by	NULL
U	NULL
,	NULL
21	NULL
was	NULL
identified	NULL
for	NULL
an	NULL
additional	NULL
patient	NULL
.	NULL

Three	NULL
new	NULL
epitopes	NULL
were	NULL
identified	NULL
in	NULL
VP16	NULL
,	NULL
a	NULL
tegument	NULL
protein	NULL
associated	NULL
with	NULL
VP22	NULL
.	NULL

Some	NULL
tegument-specific	NULL
CD4	NULL
T-cell	NULL
clones	NULL
exhibited	NULL
cytotoxic	NULL
activity	NULL
against	NULL
HSV-infected	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
herpes	NULL
simplex	NULL
tegument	NULL
proteins	NULL
are	NULL
processed	NULL
for	NULL
antigen	NULL
presentation	NULL
in	NULL
vivo	NULL
and	NULL
are	NULL
possible	NULL
candidate	NULL
compounds	NULL
for	NULL
herpes	NULL
simplex	NULL
vaccines	NULL
.	NULL

Cellular	NULL
immune	NULL
responses	NULL
are	NULL
required	NULL
to	NULL
limit	NULL
the	NULL
severity	NULL
of	NULL
recurrent	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
infections	NULL
in	NULL
humans	NULL
(	NULL
38	NULL
)	NULL
.	NULL

HSV	NULL
-specific	NULL
CD4	NULL
and	NULL
CD8	NULL
T	NULL
cells	NULL
infiltrate	NULL
herpetic	NULL
lesions	NULL
(	NULL
16	NULL
,	NULL
17	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
some	NULL
HSV	NULL
-specific	NULL
CD4	NULL
T	NULL
cells	NULL
are	NULL
cytotoxic	NULL
toward	NULL
virus-infected	NULL
cells	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

HSV-specific	NULL
CD4	NULL
T	NULL
cells	NULL
make	NULL
large	NULL
amounts	NULL
of	NULL
gamma	NULL
interferon	NULL
(	NULL
7	NULL
)	NULL
,	NULL
which	NULL
may	NULL
overcome	NULL
HSV-mediated	NULL
HLA	NULL
class	NULL
I	NULL
downregu-lation	NULL
and	NULL
permit	NULL
lysis	NULL
of	NULL
HSV-infected	NULL
cells	NULL
by	NULL
CD8	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTL	NULL
)	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Gamma	NULL
interferon	NULL
also	NULL
upregu-lates	NULL
HLA	NULL
class	NULL
II	NULL
on	NULL
HSV-infected	NULL
keratinocytes	NULL
to	NULL
allow	NULL
recognition	NULL
by	NULL
cytolytic	NULL
CD4	NULL
T	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
and	NULL
has	NULL
direct	NULL
antiviral	NULL
effects	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
antigenic	NULL
specificity	NULL
of	NULL
HSV-specific	NULL
CD4	NULL
T	NULL
cells	NULL
in	NULL
infected	NULL
humans	NULL
is	NULL
incompletely	NULL
defined	NULL
.	NULL

CD4	NULL
T-cell	NULL
responses	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
to	NULL
HSV	NULL
envelope	NULL
glycoproteins	NULL
B	NULL
,	NULL
C	NULL
,	NULL
D	NULL
,	NULL
and	NULL
H	NULL
have	NULL
been	NULL
detected	NULL
by	NULL
bulk	NULL
culture	NULL
,	NULL
limiting	NULL
dilution	NULL
,	NULL
or	NULL
clonal	NULL
analyses	NULL
(	NULL
22	NULL
,	NULL
26	NULL
,	NULL
36	NULL
,	NULL
44	NULL
)	NULL
.	NULL

PBMC-derived	NULL
CD4	NULL
T-cell	NULL
clones	NULL
(	NULL
TCC	NULL
)	NULL
commonly	NULL
recognize	NULL
envelope	NULL
glycoproteins	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
,	NULL
and	NULL
bulk	NULL
cultures	NULL
of	NULL
PBMC-derived	NULL
HSV	NULL
-specific	NULL
CD4	NULL
CTL	NULL
efficiently	NULL
recognize	NULL
glycopro-tein-expressing	NULL
target	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
determined	NULL
that	NULL
only	NULL
a	NULL
minority	NULL
of	NULL
lesion-infiltrating	NULL
CD4	NULL
TCC	NULL
recognize	NULL
glycoprotein	NULL
B	NULL
,	NULL
C	NULL
,	NULL
or	NULL
D	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
bulk	NULL
cultures	NULL
of	NULL
lesion-infiltrating	NULL
T	NULL
cells	NULL
show	NULL
reactivity	NULL
with	NULL
glycoprotein	NULL
B	NULL
or	NULL
D	NULL
for	NULL
only	NULL
50	NULL
to	NULL
70	NULL
%	NULL
of	NULL
donors	NULL
(	NULL
19	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
undertook	NULL
studies	NULL
to	NULL
define	NULL
additional	NULL
HSV	NULL
T-cell	NULL
antigens	NULL
.	NULL

The	NULL
region	NULL
near	NULL
0.7	NULL
map	NULL
units	NULL
on	NULL
the	NULL
HSV	NULL
type	NULL
2	NULL
(	NULL
HSV-2	NULL
)	NULL
genome	NULL
was	NULL
identified	NULL
as	NULL
rich	NULL
in	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
antigens	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
unique	NULL
long	NULL
(	NULL
U	NULL
;	NULL
)	NULL
48	NULL
gene	NULL
,	NULL
encoding	NULL
tegument	NULL
protein	NULL
VP16	NULL
,	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
T-cell	NULL
epitopes	NULL
(	NULL
14	NULL
)	NULL
but	NULL
does	NULL
not	NULL
account	NULL
for	NULL
all	NULL
the	NULL
antigenicity	NULL
in	NULL
this	NULL
region	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Expression	NULL
cloning	NULL
with	NULL
subgenomic	NULL
DNA	NULL
from	NULL
this	NULL
region	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Room	NULL
D3-100	NULL
,	NULL
1100	NULL
Fairview	NULL
Ave.	NULL
North	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
19024	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98109	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
206	NULL
)	NULL
667-6807	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
206	NULL
)	NULL
667-6707	NULL
.	NULL

E-mail	NULL
:	NULL
viralimm	NULL
@	NULL
u.washington.edu	NULL
.	NULL

7476	NULL
initially	NULL
identified	NULL
VP22	NULL
(	NULL
encoded	NULL
by	NULL
U	NULL
;	NULL
,	NULL
49	NULL
)	NULL
and	NULL
dUTPase	NULL
(	NULL
encoded	NULL
by	NULL
U	NULL
;	NULL
50	NULL
)	NULL
as	NULL
T-cell	NULL
antigens	NULL
.	NULL

Expression	NULL
cloning	NULL
with	NULL
full-length	NULL
viral	NULL
DNA	NULL
independently	NULL
showed	NULL
recognition	NULL
of	NULL
VP22	NULL
by	NULL
a	NULL
lesion-derived	NULL
TCC	NULL
from	NULL
a	NULL
second	NULL
donor	NULL
,	NULL
and	NULL
local	NULL
VP22-specific	NULL
responses	NULL
were	NULL
also	NULL
detected	NULL
for	NULL
a	NULL
third	NULL
donor	NULL
at	NULL
bulk	NULL
and	NULL
clonal	NULL
levels	NULL
.	NULL

Three	NULL
separate	NULL
epitopes	NULL
were	NULL
identified	NULL
in	NULL
VP22	NULL
.	NULL

Reactivity	NULL
with	NULL
an	NULL
additional	NULL
tegument	NULL
protein	NULL
,	NULL
U	NULL
,	NULL
21	NULL
,	NULL
was	NULL
also	NULL
detected	NULL
.	NULL

VP22	NULL
is	NULL
tightly	NULL
associated	NULL
with	NULL
VP16	NULL
in	NULL
the	NULL
virion	NULL
tegument	NULL
as	NULL
well	NULL
as	NULL
within	NULL
infected	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
extended	NULL
our	NULL
previous	NULL
studies	NULL
with	NULL
VP16	NULL
and	NULL
identified	NULL
three	NULL
additional	NULL
epitopes	NULL
recognized	NULL
by	NULL
lesion-infiltrating	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Viruses	NULL
and	NULL
cells	NULL
.	NULL

HSV-1	NULL
strain	NULL
E115	NULL
(	NULL
34	NULL
)	NULL
,	NULL
HSV-2	NULL
strain	NULL
333	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
intertypic	NULL
recombinant	NULL
viruses	NULL
(	NULL
IRV	NULL
)	NULL
RS1G31	NULL
(	NULL
29	NULL
)	NULL
,	NULL
DX32	NULL
(	NULL
31	NULL
)	NULL
,	NULL
and	NULL
RP-2	NULL
(	NULL
17	NULL
)	NULL
were	NULL
grown	NULL
and	NULL
titered	NULL
in	NULL
Vero	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Epstein-Barr	NULL
virus-transformed	NULL
lympho-blastoid	NULL
cell	NULL
lines	NULL
(	NULL
EBV-LCL	NULL
)	NULL
included	NULL
both	NULL
autologous	NULL
cell	NULL
lines	NULL
created	NULL
from	NULL
donors	NULL
with	NULL
genital	NULL
herpes	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
and	NULL
the	NULL
characterized	NULL
lines	NULL
AMAI	NULL
(	NULL
homozygous	NULL
for	NULL
HLA	NULL
DPB1*0402	NULL
)	NULL
,	NULL
HOM2	NULL
(	NULL
homozygous	NULL
for	NULL
HLA	NULL
DQB1*0501	NULL
)	NULL
,	NULL
MAT	NULL
(	NULL
homozygous	NULL
for	NULL
HLA	NULL
DQB1*0201	NULL
)	NULL
,	NULL
and	NULL
ARENT	NULL
(	NULL
homozygous	NULL
for	NULL
HLA	NULL
DPB1*2001	NULL
)	NULL
(	NULL
4	NULL
)	NULL
.	NULL

HSV-specific	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
after	NULL
approval	NULL
by	NULL
the	NULL
Institutional	NULL
Review	NULL
Board	NULL
.	NULL

Most	NULL
clones	NULL
were	NULL
derived	NULL
without	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
antigen	NULL
.	NULL

Donors	NULL
1	NULL
through	NULL
4	NULL
are	NULL
numbered	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
donors	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
were	NULL
the	NULL
sources	NULL
of	NULL
lesion-derived	NULL
clones	NULL
1.L3D5.10.8	NULL
,	NULL
2.3	NULL
,	NULL
and	NULL
4.2E1	NULL
,	NULL
respectively	NULL
;	NULL
clones	NULL
2.3	NULL
and	NULL
4.2E1	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Additional	NULL
lesion-derived	NULL
clones	NULL
came	NULL
from	NULL
donor	NULL
5	NULL
,	NULL
from	NULL
whose	NULL
second	NULL
,	NULL
third	NULL
,	NULL
and	NULL
fourth	NULL
lesion	NULL
samples	NULL
(	NULL
each	NULL
separated	NULL
by	NULL
1	NULL
year	NULL
)	NULL
clones	NULL
ESL2.20	NULL
,	NULL
ESL3.334	NULL
,	NULL
ESLA4.34	NULL
,	NULL
and	NULL
ESLA.9	NULL
were	NULL
derived	NULL
.	NULL

Other	NULL
clones	NULL
,	NULL
such	NULL
as	NULL
RH.13	NULL
and	NULL
KM.7	NULL
,	NULL
were	NULL
derived	NULL
from	NULL
donors	NULL
6	NULL
and	NULL
7	NULL
.	NULL

Clones	NULL
2.3	NULL
,	NULL
4.2E1	NULL
,	NULL
ESL2.20	NULL
,	NULL
RH.13	NULL
,	NULL
and	NULL
KM.17	NULL
were	NULL
derived	NULL
directly	NULL
from	NULL
herpetic	NULL
vesicle	NULL
fluid	NULL
(	NULL
16	NULL
)	NULL
.	NULL

To	NULL
derive	NULL
CD4	NULL
TCC	NULL
ESLA.9	NULL
,	NULL
biopsy	NULL
of	NULL
a	NULL
recurrent	NULL
genital	NULL
HSV-2	NULL
lesion	NULL
(	NULL
day	NULL
3	NULL
of	NULL
symptoms	NULL
)	NULL
was	NULL
performed	NULL
and	NULL
bulk	NULL
lesion-infiltrating	NULL
cells	NULL
were	NULL
expanded	NULL
with	NULL
phytohemagglu-tinin	NULL
and	NULL
interleukin	NULL
2	NULL
(	NULL
Schiaperelli	NULL
Biosystems	NULL
,	NULL
Columbia	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
of	NULL
acyclovir	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
19	NULL
)	NULL
.	NULL

After	NULL
16	NULL
days	NULL
,	NULL
cells	NULL
were	NULL
cloned	NULL
at	NULL
1	NULL
cell/well	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Previously	NULL
described	NULL
VP16-specific	NULL
clones	NULL
1A.B.25	NULL
,	NULL
ESL3.334	NULL
,	NULL
and	NULL
ESLA4.34	NULL
(	NULL
8	NULL
,	NULL
14	NULL
,	NULL
18	NULL
)	NULL
were	NULL
similarly	NULL
derived	NULL
from	NULL
bulk	NULL
cultures	NULL
.	NULL

Some	NULL
clones	NULL
were	NULL
derived	NULL
by	NULL
using	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
antigen	NULL
.	NULL

To	NULL
derive	NULL
additional	NULL
TCC	NULL
from	NULL
donor	NULL
1	NULL
(	NULL
17	NULL
)	NULL
,	NULL
phytohemagglutinin-driven	NULL
bulk	NULL
cultures	NULL
were	NULL
prepared	NULL
from	NULL
each	NULL
of	NULL
four	NULL
2-mm	NULL
biopsy	NULL
specimens	NULL
(	NULL
day	NULL
5	NULL
of	NULL
symptoms	NULL
)	NULL
obtained	NULL
6	NULL
years	NULL
after	NULL
the	NULL
occurrence	NULL
of	NULL
the	NULL
lesion	NULL
from	NULL
which	NULL
clone	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
1A.B.25	NULL
(	NULL
mentioned	NULL
above	NULL
)	NULL
was	NULL
derived	NULL
.	NULL

After	NULL
16	NULL
days	NULL
,	NULL
1.5	NULL
X	NULL
10°	NULL
bulk	NULL
lymphocytes	NULL
from	NULL
one	NULL
biopsy	NULL
culture	NULL
were	NULL
stimulated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
HSV-2	NULL
VP22	NULL
,	NULL
amino	NULL
acids	NULL
105	NULL
to	NULL
190	NULL
(	NULL
VP22	NULL
105-190	NULL
)	NULL
/ml	NULL
(	NULL
see	NULL
below	NULL
)	NULL
and	NULL
an	NULL
equal	NULL
number	NULL
of	NULL
autologous	NULL
irradiated	NULL
(	NULL
3,300	NULL
rads	NULL
)	NULL
PBMC	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
T-cell	NULL
medium	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Interleukin	NULL
2	NULL
(	NULL
32	NULL
U/ml	NULL
)	NULL
was	NULL
added	NULL
starting	NULL
on	NULL
day	NULL
6	NULL
.	NULL

TCC	NULL
1.L3D5.10.8	NULL
was	NULL
isolated	NULL
from	NULL
this	NULL
line	NULL
on	NULL
day	NULL
12	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
16	NULL
)	NULL
.	NULL

To	NULL
create	NULL
PBMC-derived	NULL
TCC	NULL
and	NULL
BM.17	NULL
,	NULL
1.5	NULL
x	NULL
10°	NULL
PBMC	NULL
of	NULL
HSV-2-seropositive	NULL
donors	NULL
8	NULL
and	NULL
9	NULL
were	NULL
stimulated	NULL
for	NULL
12	NULL
days	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
baculovirus-derived	NULL
full-length	NULL
VP16/ml	NULL
in	NULL
24-well	NULL
plates	NULL
;	NULL
responding	NULL
cells	NULL
were	NULL
cloned	NULL
at	NULL
1	NULL
cell/well	NULL
.	NULL

TCC	NULL
and	NULL
lines	NULL
were	NULL
used	NULL
10	NULL
to	NULL
14	NULL
days	NULL
after	NULL
the	NULL
last	NULL
stimulation	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
negative	NULL
for	NULL
mycoplasmas	NULL
except	NULL
ARENT	NULL
.	NULL

ARENT	NULL
was	NULL
initially	NULL
positive	NULL
for	NULL
mycoplasmas	NULL
by	NULL
DNA	NULL
probe	NULL
test	NULL
(	NULL
Genprobe	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
and	NULL
was	NULL
treated	NULL
with	NULL
ciprofloxacin	NULL
at	NULL
10	NULL
ug/ml	NULL
(	NULL
12	NULL
)	NULL
for	NULL
2	NULL
weeks	NULL
prior	NULL
to	NULL
utilization	NULL
,	NULL
with	NULL
conversion	NULL
of	NULL
the	NULL
test	NULL
to	NULL
negative	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

Flow	NULL
cytometry	NULL
used	NULL
a	NULL
combination	NULL
of	NULL
murine	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
MAb	NULL
)	NULL
to	NULL
human	NULL
CD4	NULL
(	NULL
clone	NULL
SFCI	NULL
12T4D11	NULL
)	NULL
and	NULL
CD8	NULL
(	NULL
clone	NULL
SFCI	NULL
21Thy2D3	NULL
,	NULL
recognizing	NULL
the	NULL
a	NULL
chain	NULL
of	NULL
human	NULL
CD8	NULL
)	NULL
(	NULL
Coulter	NULL
,	NULL
Hialeah	NULL
,	NULL
Fla.	NULL
)	NULL
.	NULL

Immunoblotting	NULL
.	NULL

Lysates	NULL
of	NULL
HSV-infected	NULL
Vero	NULL
cells	NULL
were	NULL
prepared	NULL
,	NULL
electro-phoresed	NULL
through	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-10	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
blocked	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
-0.05	NULL
%	NULL
Tween	NULL
20-1	NULL
%	NULL
nonfat	NULL
dried	NULL
milk	NULL
.	NULL

Antigen	NULL
was	NULL
detected	NULL
by	NULL
sequential	NULL
incubation	NULL
with	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
MAb	NULL
P43	NULL
,	NULL
specific	NULL
for	NULL
the	NULL
U	NULL
;	NULL
49	NULL
gene	NULL
product	NULL
,	NULL
VP22	NULL
(	NULL
11	NULL
)	NULL
,	NULL
affinity-purified	NULL
goat	NULL
anti-mouse	NULL
immunoglobulin	NULL
M-peroxidase	NULL
conjugate	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

,	NULL
and	NULL
the	NULL
TMB	NULL
substrate	NULL
system	NULL
(	NULL
Kirkegaard	NULL
and	NULL
Perry	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

with	NULL
three	NULL
washes	NULL
(	NULL
5	NULL
min	NULL
each	NULL
)	NULL
in	NULL
PBS-Tween	NULL
between	NULL
each	NULL
step	NULL
.	NULL

Viral	NULL
DNA	NULL
libraries	NULL
and	NULL
cloning	NULL
.	NULL

For	NULL
subgenomic	NULL
DNA	NULL
,	NULL
the	NULL
HSV-2	NULL
strain	NULL
HG-52	NULL
BamHI	NULL
w	NULL
fragment	NULL
was	NULL
subcloned	NULL
from	NULL
the	NULL
Bg/II	NULL
i	NULL
fragment	NULL
and	NULL
gel	NULL
purified	NULL
.	NULL

Viral	NULL
DNA	NULL
was	NULL
digested	NULL
with	NULL
SmaI	NULL
,	NULL
BamHI	NULL
ends	NULL
were	NULL
blunted	NULL
with	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
,	NULL
and	NULL
DNA	NULL
fragments	NULL
were	NULL
purified	NULL
by	NULL
phenol	NULL
extraction	NULL
and	NULL
alcohol	NULL
precipitation	NULL
.	NULL

For	NULL
whole-virus	NULL
DNA	NULL
,	NULL
confluent	NULL
Vero	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HSV-2	NULL
strain	NULL
HGS52	NULL
.	NULL

Total	NULL
nucleic	NULL
acids	NULL
from	NULL
three	NULL
150-cm	NULL
>	NULL
cell	NULL
cultures	NULL
were	NULL
prepared	NULL
by	NULL
proteinase	NULL
K	NULL
digestion	NULL
,	NULL
chloroform-phenol	NULL
extraction	NULL
,	NULL
and	NULL
isopropanol	NULL
precipitation	NULL
.	NULL

The	NULL
resultant	NULL
material	NULL
was	NULL
treated	NULL
with	NULL
RNAse	NULL
H	NULL
and	NULL
was	NULL
reextracted	NULL
and	NULL
precipitated	NULL
.	NULL

Aliquots	NULL
(	NULL
1	NULL
pg	NULL
)	NULL
of	NULL
HGS2	NULL
DNA	NULL
were	NULL
digested	NULL
with	NULL
Smal	NULL
or	NULL
Alul	NULL
,	NULL
and	NULL
80	NULL
%	NULL
of	NULL
these	NULL
digests	NULL
were	NULL
combined	NULL
and	NULL
recovered	NULL
as	NULL
described	NULL
above	NULL
for	NULL
creation	NULL
of	NULL
expression	NULL
libraries	NULL
.	NULL

Expression	NULL
cloning	NULL
used	NULL
pUEX	NULL
vectors	NULL
(	NULL
5	NULL
)	NULL
.	NULL

pUEX1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
DNAs	NULL
were	NULL
linearized	NULL
with	NULL
SmaI	NULL
,	NULL
dephosphorylated	NULL
with	NULL
calf	NULL
intestinal	NULL
phosphatase	NULL
,	NULL
and	NULL
gel	NULL
purified	NULL
.	NULL

Approximately	NULL
100	NULL
ng	NULL
of	NULL
vector	NULL
and	NULL
500	NULL
ng	NULL
of	NULL
DNA	NULL
fragments	NULL
were	NULL
ligated	NULL
,	NULL
and	NULL
10	NULL
%	NULL
of	NULL
ethanol-precipitated	NULL
reaction	NULL
mixtures	NULL
were	NULL
used	NULL
to	NULL
transform	NULL
Escherichia	NULL
coli	NULL
DH1O0	NULL
Electromax	NULL
(	NULL
GIBCO	NULL
)	NULL
by	NULL
electroporation	NULL
(	NULL
BTX	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
in	NULL
1-mm	NULL
cuvettes	NULL
.	NULL

After	NULL
1	NULL
h	NULL
of	NULL
recovery	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
SOC	NULL
medium	NULL
,	NULL
portions	NULL
were	NULL
frozen	NULL
as	NULL
glycerol	NULL
stocks	NULL
(	NULL
100	NULL
pl	NULL
each	NULL
)	NULL
,	NULL
titered	NULL
on	NULL
ampicillin	NULL
plates	NULL
at	NULL
30°C	NULL
(	NULL
250	NULL
p1	NULL
)	NULL
,	NULL
or	NULL
used	NULL
directly	NULL
(	NULL
250	NULL
wl	NULL
)	NULL
for	NULL
protein	NULL
induction	NULL
to	NULL
create	NULL
fusion	NULL
protein	NULL
libraries	NULL
.	NULL

Several	NULL
thousand	NULL
ampicillin-resistant	NULL
colonies	NULL
were	NULL
isolated	NULL
per	NULL
transformation	NULL
.	NULL

To	NULL
amplify	NULL
genomic	NULL
libraries	NULL
,	NULL
glycerol	NULL
stocks	NULL
were	NULL
grown	NULL
overnight	NULL
at	NULL
30°C	NULL
in	NULL
2	NULL
%	NULL
YT-ampicillin	NULL
medium	NULL
and	NULL
refrozen	NULL
.	NULL

Confirmatory	NULL
subcloning	NULL
of	NULL
VP22	NULL
105-190	NULL
,	NULL
U	NULL
;	NULL
,	NULL
50	NULL
118-312	NULL
,	NULL
and	NULL
U	NULL
;	NULL
50	NULL
118-250	NULL
was	NULL
performed	NULL
by	NULL
isolating	NULL
the	NULL
262-bp	NULL
Smal-Sful	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
49	NULL
,	NULL
the	NULL
583-bp	NULL
Smal	NULL
fragment	NULL
of	NULL
U	NULL
,	NULL
50	NULL
,	NULL
and	NULL
the	NULL
397-bp	NULL
Smal-Stul	NULL
fragment	NULL
of	NULL
Uj	NULL
50	NULL
,	NULL
respec-tively	NULL
.	NULL

Fragments	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
appropriate	NULL
linearized	NULL
,	NULL
gel-purified	NULL
pUEX	NULL
vector	NULL
,	NULL
and	NULL
protein	NULL
was	NULL
expressed	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
DHSa	NULL
.	NULL

Constructs	NULL
were	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

Antigens	NULL
.	NULL

Whole-virus	NULL
preparations	NULL
containing	NULL
10°	NULL
to	NULL
10°	NULL
PFU/ml	NULL
were	NULL
UV	NULL
inactivated	NULL
for	NULL
30	NULL
min	NULL
(	NULL
16	NULL
)	NULL
and	NULL
used	NULL
at	NULL
a	NULL
1:100	NULL
final	NULL
dilution	NULL
.	NULL

Peptides	NULL
of	NULL
VP22	NULL
were	NULL
synthesized	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
18	NULL
)	NULL
and	NULL
used	NULL
as	NULL
stocks	NULL
at	NULL
2	NULL
mg/ml	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
.	NULL

Peptides	NULL
of	NULL
U	NULL
;	NULL
48	NULL
,	NULL
13	NULL
amino	NULL
acids	NULL
long	NULL
and	NULL
overlapping	NULL
by	NULL
4	NULL
amino	NULL
acids	NULL
,	NULL
and	NULL
VP16	NULL
of	NULL
HSV-2	NULL
,	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
416	NULL
,	NULL
and	NULL
full-length	NULL
VP16	NULL
,	NULL
both	NULL
expressed	NULL
in	NULL
baculovirus	NULL
,	NULL
were	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
Rac	NULL
L.	NULL
Burke	NULL
and	NULL
Michael	NULL
Tigges	NULL
,	NULL
Chiron	NULL
Corporation	NULL
,	NULL
Emeryville	NULL
,	NULL
Calif.	NULL
Bacterium-derived	NULL
protein	NULL
antigen	NULL
expression	NULL
was	NULL
induced	NULL
for	NULL
2	NULL
h	NULL
at	NULL
42°C	NULL
in	NULL
cells	NULL
growing	NULL
logarithmically	NULL
(	NULL
optical	NULL
density	NULL
at	NULL
600	NULL
nm	NULL
,	NULL
0.4	NULL
to	NULL
0.6	NULL
)	NULL
in	NULL
2	NULL
%	NULL
YT-ampicillin	NULL
broth	NULL
at	NULL
30°C	NULL
.	NULL

Protein	NULL
was	NULL
purified	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
27	NULL
)	NULL
,	NULL
omitting	NULL
gel	NULL
purification	NULL
.	NULL

Bacterial	NULL
cultures	NULL
of	NULL
50	NULL
ml	NULL
(	NULL
libraries	NULL
)	NULL
or	NULL
5-	NULL
to	NULL
10-ml	NULL
cultures	NULL
(	NULL
pools	NULL
and	NULL
clones	NULL
)	NULL
yielded	NULL
fine	NULL
particulate	NULL
suspensions	NULL
in	NULL
200	NULL
to	NULL
400	NULL
ul	NULL
of	NULL
PBS	NULL
(	NULL
Ca	NULL
and	NULL
Mg	NULL
free	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
bicinchoninic	NULL
acid	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IIl	NULL
.	NULL
)	NULL

after	NULL
proteins	NULL
were	NULL
solubilized	NULL
in	NULL
1	NULL
%	NULL
SDS	NULL
at	NULL
60°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
heat-induced	NULL
bacteria	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
PBS-10	NULL
mM	NULL
EDTA	NULL
,	NULL
heated	NULL
to	NULL
56°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
and	NULL
washed	NULL
in	NULL
PBS	NULL
prior	NULL
to	NULL
use	NULL
as	NULL
antigens	NULL
.	NULL

After	NULL
identification	NULL
of	NULL
an	NULL
active	NULL
library	NULL
of	NULL
viral	NULL
DNA	NULL
,	NULL
antigen	NULL
identification	NULL
used	NULL
30	NULL
to	NULL
60	NULL
clones	NULL
for	NULL
subgenomic	NULL
viral	NULL
DNA	NULL
fragments	NULL
or	NULL
2,000	NULL
to	NULL
3,000	NULL
clones	NULL
for	NULL
full-length	NULL
viral	NULL
DNA	NULL
.	NULL

For	NULL
the	NULL
less	NULL
complex	NULL
library	NULL
,	NULL
1-ml	NULL
cultures	NULL
of	NULL
each	NULL
clone	NULL
were	NULL
processed	NULL
as	NULL
pools	NULL
of	NULL
six	NULL
to	NULL
eight	NULL
clones	NULL
.	NULL

Individual	NULL
clones	NULL
within	NULL
the	NULL
active	NULL
pool	NULL
,	NULL
and	NULL
confirmatory	NULL
subclones	NULL
containing	NULL
known	NULL
viral	NULL
DNA	NULL
frag-ments	NULL
,	NULL
were	NULL
processed	NULL
as	NULL
5-ml	NULL
cultures	NULL
.	NULL

A	NULL
combinatorial	NULL
method	NULL
(	NULL
27	NULL
)	NULL
was	NULL
used	NULL
to	NULL
screen	NULL
libraries	NULL
from	NULL
whole-virus	NULL
DNA	NULL
.	NULL

Glycerol	NULL
stocks	NULL
of	NULL
amplified	NULL
libraries	NULL
of	NULL
transformed	NULL
bacteria	NULL
were	NULL
titered	NULL
on	NULL
ampicillin	NULL
plates	NULL
;	NULL
20	NULL
to	NULL
30	NULL
colonies/well	NULL
were	NULL
cultured	NULL
overnight	NULL
at	NULL
30°C	NULL
in	NULL
a	NULL
96-well	NULL
plate	NULL
in	NULL
a	NULL
rotating	NULL
shaker	NULL
.	NULL

Cultures	NULL
were	NULL
diluted	NULL
1:100	NULL
into	NULL
1-ml	NULL
cultures	NULL
,	NULL
and	NULL
fusion	NULL
protein	NULL
synthesis	NULL
was	NULL
induced	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Portions	NULL
(	NULL
400	NULL
wl	NULL
)	NULL
of	NULL
cultures	NULL
were	NULL
pooled	NULL
row-	NULL
and	NULL
colum-	NULL
CD4	NULL
T	NULL
CELLS	NULL
SPECIFIC	NULL
FOR	NULL
HSV-2	NULL
TEGUMENT	NULL
PROTEINS	NULL
-	NULL
7477	NULL
nwise	NULL
for	NULL
protein	NULL
purification	NULL
and	NULL
evaluation	NULL
in	NULL
lymphoproliferation	NULL
assays	NULL
.	NULL

If	NULL
more	NULL
than	NULL
one	NULL
row	NULL
and	NULL
column	NULL
were	NULL
positive	NULL
,	NULL
wells	NULL
at	NULL
the	NULL
intersections	NULL
of	NULL
positive	NULL
rows	NULL
and	NULL
one	NULL
positive	NULL
column	NULL
were	NULL
used	NULL
to	NULL
prepare	NULL
protein	NULL
from	NULL
5-	NULL
to	NULL
10-ml	NULL
cultures	NULL
to	NULL
definitively	NULL
identify	NULL
a	NULL
positive	NULL
well	NULL
.	NULL

Cultures	NULL
(	NULL
n	NULL
=	NULL
96	NULL
colonies	NULL
)	NULL
of	NULL
bacteria	NULL
were	NULL
derived	NULL
from	NULL
ampicillin	NULL
plates	NULL
seeded	NULL
with	NULL
diluted	NULL
broth	NULL
from	NULL
positive	NULL
wells	NULL
.	NULL

These	NULL
were	NULL
evaluated	NULL
as	NULL
pools	NULL
(	NULL
of	NULL
12	NULL
bacterial	NULL
colonies	NULL
)	NULL
and	NULL
then	NULL
individual	NULL
clones	NULL
.	NULL

Lymphocyte	NULL
functional	NULL
assays	NULL
.	NULL

Triplicate	NULL
proliferation	NULL
assay	NULL
wells	NULL
contained	NULL
10+	NULL
cloned	NULL
T	NULL
cells	NULL
,	NULL
10°	NULL
irradiated	NULL
(	NULL
3,300	NULL
rads	NULL
)	NULL
PBMC	NULL
,	NULL
or	NULL
2.5	NULL
X	NULL
10	NULL
irradiated	NULL
(	NULL
8,000	NULL
rads	NULL
)	NULL
EBV-LCL	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
and	NULL
antigen	NULL
in	NULL
200	NULL
pl	NULL
of	NULL
T-cell	NULL
medium	NULL
(	NULL
18	NULL
)	NULL
in	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
.	NULL

When	NULL
heat-killed	NULL
bacteria	NULL
were	NULL
used	NULL
as	NULL
the	NULL
antigen	NULL
,	NULL
the	NULL
equivalent	NULL
of	NULL
10°	NULL
CFU/well	NULL
(	NULL
prior	NULL
to	NULL
inactivation	NULL
)	NULL
was	NULL
added	NULL
and	NULL
gentamicin	NULL
(	NULL
20	NULL
pg/ml	NULL
)	NULL
was	NULL
included	NULL
.	NULL

After	NULL
72	NULL
h	NULL
,	NULL
1	NULL
Ci	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thy-midine/well	NULL
was	NULL
added	NULL
for	NULL
18	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
thymidine	NULL
was	NULL
evaluated	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Standard	NULL
deviations	NULL
were	NULL
less	NULL
than	NULL
10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
values	NULL
.	NULL

Results	NULL
are	NULL
reported	NULL
as	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
or	NULL
as	NULL
change	NULL
in	NULL
counts	NULL
per	NULL
minute	NULL
(	NULL
Acpm	NULL
)	NULL
,	NULL
equal	NULL
to	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
for	NULL
the	NULL
experimental	NULL
antigen	NULL
minus	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
for	NULL
the	NULL
control	NULL
antigen	NULL
.	NULL

The	NULL
control	NULL
antigen	NULL
was	NULL
mock-infected	NULL
cell	NULL
lysate	NULL
for	NULL
whole-virus	NULL
antigens	NULL
and	NULL
pUEX2-derived	NULL
B-galactosidase	NULL
for	NULL
recombinant	NULL
protein	NULL
preparations	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
reactivity	NULL
of	NULL
bulk-cultured	NULL
lesion-derived	NULL
T	NULL
cells	NULL
,	NULL
fusion	NULL
proteins	NULL
or	NULL
control	NULL
B-galactosidase	NULL
was	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
.	NULL

Glycoproteins	NULL
B	NULL
and	NULL
D	NULL
and	NULL
VP16	NULL
of	NULL
HSV-2	NULL
were	NULL
used	NULL
at	NULL
1	NULL
ug/ml	NULL
,	NULL
and	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
HLA-restricting	NULL
loci	NULL
,	NULL
HLA-DR-specific	NULL
MAb	NULL
L243	NULL
(	NULL
32	NULL
)	NULL
,	NULL
HLA-DP-specific	NULL
MAb	NULL
B7.21	NULL
(	NULL
37	NULL
)	NULL
,	NULL
or	NULL
HLA-DQ-specific	NULL
MAb	NULL
SPV-L3	NULL
(	NULL
33	NULL
)	NULL
was	NULL
used	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Cytolysis	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
by	NULL
using	NULL
4-h	NULL
``	NULL
Cr	NULL
release	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Target	NULL
EBV-LCL	NULL
were	NULL
infected	NULL
for	NULL
18	NULL
h	NULL
with	NULL
HSV-2	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
30	NULL
or	NULL
pulsed	NULL
with	NULL
1.0	NULL
M	NULL
peptide	NULL
for	NULL
90	NULL
min	NULL
prior	NULL
to	NULL
washing	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
effector-to-target	NULL
ratio	NULL
was	NULL
20:1	NULL
.	NULL

Spontancous	NULL
release	NULL
was	NULL
less	NULL
than	NULL
28	NULL
%	NULL
.	NULL

DNA	NULL
sequencing	NULL
.	NULL

Viral	NULL
inserts	NULL
in	NULL
plasmids	NULL
in	NULL
bacteria	NULL
yielding	NULL
active	NULL
proteins	NULL
were	NULL
completely	NULL
sequenced	NULL
(	NULL
Taq	NULL
DyeDeoxy	NULL
FS	NULL
kit	NULL
;	NULL
Perkin-Elmer	NULL
ABI	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
Calif.	NULL
)	NULL
in	NULL
both	NULL
directions	NULL
by	NULL
starting	NULL
with	NULL
primers	NULL
CATGGCTGAATATC	NULL
GACGGT	NULL
(	NULL
5	NULL
'	NULL
end	NULL
of	NULL
insert	NULL
)	NULL
and	NULL
CTAGAGCCGGATCGATCCGGTC	NULL
(	NULL
3	NULL
'	NULL
end	NULL
of	NULL
insert	NULL
)	NULL
and	NULL
then	NULL
using	NULL
internal	NULL
primers	NULL
designed	NULL
as	NULL
required	NULL
.	NULL

HLA	NULL
typing	NULL
.	NULL

HLA-DR	NULL
and	NULL
-DQ	NULL
typing	NULL
was	NULL
performed	NULL
at	NULL
class	NULL
II	NULL
alleles	NULL
by	NULL
serologic	NULL
methods	NULL
or	NULL
at	NULL
the	NULL
DNA	NULL
level	NULL
by	NULL
reverse	NULL
dot	NULL
blot	NULL
hybridization	NULL
(	NULL
25	NULL
)	NULL
.	NULL

HLA-DP	NULL
typing	NULL
was	NULL
performed	NULL
by	NULL
sequencing	NULL
(	NULL
HLA-DP	NULL
kit	NULL
;	NULL
Perkin-Elmer	NULL
ABI	NULL
)	NULL
.	NULL

RESULTS	NULL
Fine	NULL
localization	NULL
of	NULL
T-cell	NULL
epitopes	NULL
.	NULL

To	NULL
reduce	NULL
the	NULL
complexity	NULL
of	NULL
libraries	NULL
for	NULL
expression	NULL
cloning	NULL
,	NULL
we	NULL
selected	NULL
a	NULL
TCC-rec-ognizing	NULL
antigen	NULL
(	NULL
s	NULL
)	NULL
partially	NULL
mapped	NULL
by	NULL
using	NULL
HSV-1	NULL
X	NULL
HSV-2	NULL
IRV	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
determined	NULL
that	NULL
HSV	NULL
DNA	NULL
near	NULL
0.7	NULL
map	NULL
units	NULL
encodes	NULL
T-cell	NULL
antigens	NULL
in	NULL
addition	NULL
to	NULL
VP16	NULL
.	NULL

Epitope	NULL
mapping	NULL
for	NULL
TCC	NULL
4.2E1	NULL
and	NULL
2.3	NULL
(	NULL
17	NULL
)	NULL
was	NULL
improved	NULL
with	NULL
IRV	NULL
DX32	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
HSV-2-based	NULL
virus	NULL
contains	NULL
a	NULL
block	NULL
of	NULL
HSV-1	NULL
DNA	NULL
near	NULL
0.7	NULL
map	NULL
units	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
U	NULL
,	NULL
48	NULL
gene	NULL
product	NULL
has	NULL
the	NULL
HSV-2	NULL
phenotype	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
reactivity	NULL
with	NULL
the	NULL
HSV-2	NULL
type-specific	NULL
,	NULL
VP16-specific	NULL
(	NULL
17	NULL
)	NULL
TCC	NULL
1A.B.25	NULL
.	NULL

The	NULL
U	NULL
;	NULL
,	NULL
49	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
U	NULL
,	NULL
50	NULL
gene	NULL
products	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
also	NULL
have	NULL
an	NULL
HSV-2	NULL
phenotype	NULL
.	NULL

The	NULL
HSV-2	NULL
DNA	NULL
present	NULL
in	NULL
IRV	NULL
DX32	NULL
therefore	NULL
includes	NULL
U	NULL
;	NULL
48	NULL
,	NULL
U	NULL
,	NULL
49	NULL
,	NULL
U	NULL
;	NULL
50	NULL
,	NULL
and	NULL
most	NULL
likely	NULL
the	NULL
intervening	NULL
U	NULL
;	NULL
,	NULL
49.5	NULL
.	NULL

Since	NULL
TCC	NULL
4.2E1	NULL
and	NULL
2.3	NULL
react	NULL
with	NULL
RS1G31	NULL
and	NULL
DX32	NULL
,	NULL
but	NULL
not	NULL
with	NULL
RP2	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
recognition	NULL
of	NULL
U	NULL
,	NULL
49	NULL
,	NULL
U	NULL
,	NULL
49.5	NULL
,	NULL
or	NULL
U	NULL
;	NULL
50	NULL
is	NULL
most	NULL
likely	NULL
.	NULL

Expression	NULL
cloning	NULL
to	NULL
determine	NULL
T-cell	NULL
antigens	NULL
.	NULL

The	NULL
BamHI	NULL
w	NULL
fragment	NULL
of	NULL
HSV-2	NULL
was	NULL
selected	NULL
for	NULL
expression	NULL
cloning	NULL
,	NULL
since	NULL
it	NULL
contains	NULL
the	NULL
U	NULL
;	NULL
49	NULL
and	NULL
U	NULL
,	NULL
49.5	NULL
coding	NULL
sequences	NULL
and	NULL
most	NULL
of	NULL
the	NULL
U	NULL
;	NULL
50	NULL
coding	NULL
sequence	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Seventy	NULL
to	NULL
ninety	NULL
percent	NULL
of	NULL
random	NULL
colonies	NULL
contained	NULL
an	NULL
insert	NULL
;	NULL
all	NULL
were	NULL
of	NULL
viral	NULL
origin	NULL
.	NULL

The	NULL
most	NULL
active	NULL
libraries	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
for	NULL
each	NULL
TCC	NULL
(	NULL
pUEX1	NULL
for	NULL
TCC	NULL
4.2E1	NULL
and	NULL
pUEX3	NULL
for	NULL
TCC	NULL
2.3	NULL
)	NULL
were	NULL
se-lected	NULL
,	NULL
and	NULL
an	NULL
individual	NULL
reactive	NULL
bacterial	NULL
clone	NULL
was	NULL
detected	NULL
by	NULL
sequential	NULL
testing	NULL
of	NULL
pools	NULL
and	NULL
individual	NULL
colonies	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Clone	NULL
1.1.3	NULL
encodes	NULL
a	NULL
fusion	NULL
protein	NULL
eliciting	NULL
proliferation	NULL
by	NULL
TCC	NULL
4.2E1	NULL
.	NULL

This	NULL
clone	NULL
contains	NULL
a	NULL
backwards	NULL
80-bp	NULL
Smal	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
49	NULL
,	NULL
a	NULL
262-bp	NULL
Smal	NULL
fragment	NULL
of	NULL
HSV-2	NULL
U	NULL
,	NULL
49	NULL
DNA	NULL
predicted	NULL
to	NULL
encode	NULL
amino	NULL
acids	NULL
105	NULL
to	NULL
190	NULL
,	NULL
forward	NULL
and	NULL
in	NULL
frame	NULL
with	NULL
regard	NULL
to	NULL
B-galactosidase	NULL
,	NULL
and	NULL
a	NULL
246-bp	NULL
Smal	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
49	NULL
forward	NULL
but	NULL
out	NULL
of	NULL
frame	NULL
due	NULL
to	NULL
a	NULL
deletion	NULL
of	NULL
a	NULL
7478	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

«	NULL
-	NULL
HSV-2	NULL
BamH	NULL
|	NULL
w	NULL
RP-2	NULL
RS1G31	NULL
DX32	NULL
~-	NULL
HSV-2	NULL
U	NULL
,	NULL
<	NULL
4	NULL
--	NULL
-	NULL
<	NULL
--	NULL
<	NULL
-	NULL
<	NULL
4	NULL
-P	NULL
-P	NULL
--	NULL
-	NULL
»	NULL
Uy	NULL
ORF	NULL
47	NULL
48	NULL
49	NULL
49.5	NULL
50	NULL
51	NULL
52	NULL
OHSV-1	NULL
1	NULL
A	NULL
&	NULL
B	NULL
_2	NULL
5	NULL
i	NULL
A	NULL
wa	NULL
4	NULL
&	NULL
2	NULL
E	NULL
1	NULL
l	NULL
M	NULL
R	NULL
S	NULL
1	NULL
G	NULL
3	NULL
1	NULL
O	NULL
-	NULL
H	NULL
DX32	NULL
F	NULL
lle	NULL
eat	NULL
p	NULL
*	NULL
ZAMHSV-2	NULL
WHo	NULL
r	NULL
rammer	NULL
tar	NULL
E	NULL
S	NULL
L4	NULL
.9	NULL
diy	NULL
t	NULL
tt	NULL
peeve	NULL
tatt	NULL
C	NULL
6	NULL
U	NULL
¥	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
Top	NULL
)	NULL
Organization	NULL
of	NULL
the	NULL
HSV	NULL
genome	NULL
in	NULL
the	NULL
region	NULL
of	NULL
map	NULL
units	NULL
0.67	NULL
to	NULL
0.73	NULL
.	NULL

Boundaries	NULL
are	NULL
approximate	NULL
.	NULL

HSV-1	NULL
X	NULL
HSV-2	NULL
IRV	NULL
are	NULL
also	NULL
shown	NULL
.	NULL

HSV-2	NULL
DNA	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
solid	NULL
line	NULL
,	NULL
HSV-1	NULL
DNA	NULL
by	NULL
a	NULL
dashed	NULL
line	NULL
,	NULL
and	NULL
indeterminate	NULL
regions	NULL
by	NULL
multiple	NULL
lines	NULL
.	NULL

The	NULL
HSV-2	NULL
BamHI	NULL
w	NULL
fragment	NULL
used	NULL
for	NULL
expression	NULL
cloning	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

ORF	NULL
,	NULL
open	NULL
reading	NULL
frame	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
Proliferative	NULL
responses	NULL
of	NULL
TCC	NULL
to	NULL
the	NULL
indicated	NULL
IRV	NULL
.	NULL

Data	NULL
are	NULL
Acpm	NULL
,	NULL
expressing	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
the	NULL
medium	NULL
,	NULL
which	NULL
was	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
in	NULL
each	NULL
case	NULL
.	NULL

single	NULL
C	NULL
residue	NULL
at	NULL
the	NULL
262-bp	NULL
SmaI	NULL
fragment-242-bp	NULL
Smal	NULL
fragment	NULL
junction	NULL
.	NULL

Clone	NULL
3.19	NULL
contained	NULL
a	NULL
583-bp	NULL
Smal	NULL
fragment	NULL
encoding	NULL
amino	NULL
acids	NULL
118	NULL
to	NULL
312	NULL
of	NULL
U	NULL
,	NULL
50	NULL
,	NULL
followed	NULL
by	NULL
backwards	NULL
80-	NULL
and	NULL
96-bp	NULL
SmaI	NULL
fragments	NULL
of	NULL
U	NULL
,	NULL
49	NULL
.	NULL

Identification	NULL
of	NULL
T-cell	NULL
antigens	NULL
was	NULL
confirmed	NULL
by	NULL
targeted	NULL
subcloning	NULL
and	NULL
overlapping	NULL
peptides	NULL
.	NULL

The	NULL
262-bp	NULL
SmaI	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
,	NULL
49	NULL
of	NULL
HSV-2	NULL
encoding	NULL
amino	NULL
acids	NULL
105	NULL
to	NULL
190	NULL
was	NULL
subcloned	NULL
into	NULL
pUEX3	NULL
to	NULL
yield	NULL
plasmid	NULL
49.262.12	NULL
.	NULL

This	NULL
protein	NULL
stimulated	NULL
TCC	NULL
4.2E1	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Only	NULL
peptide	NULL
105-126	NULL
of	NULL
VP22	NULL
of	NULL
HSV-2	NULL
(	NULL
GGPVGAGGRSHAPPARTPKMTR	NULL
)	NULL
was	NULL
stimulatory	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

DNA	NULL
fragments	NULL
encoding	NULL
U	NULL
,	NULL
50	NULL
118-312	NULL
and	NULL
118-250	NULL
were	NULL
subcloned	NULL
into	NULL
pUEX3	NULL
.	NULL

Fusion	NULL
proteins	NULL
expressing	NULL
these	NULL
fragments	NULL
were	NULL
active	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Evaluation	NULL
of	NULL
random	NULL
colonies	NULL
from	NULL
full-length	NULL
HSV-2	NULL
DNA	NULL
libraries	NULL
showed	NULL
that	NULL
80	NULL
to	NULL
100	NULL
%	NULL
contained	NULL
plasmids	NULL
with	NULL
an	NULL
insert	NULL
;	NULL
80	NULL
to	NULL
100	NULL
%	NULL
of	NULL
inserts	NULL
were	NULL
of	NULL
viral	NULL
origin	NULL
.	NULL

For	NULL
both	NULL
TCC	NULL
ESLA.9	NULL
and	NULL
ESL2.20	NULL
,	NULL
only	NULL
the	NULL
pUEX3	NULL
protein	NULL
library	NULL
elicited	NULL
lymphoproliferation	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
libraries	NULL
were	NULL
more	NULL
complex	NULL
than	NULL
those	NULL
made	NULL
from	NULL
the	NULL
BamHI	NULL
w	NULL
fragment	NULL
,	NULL
2,000	NULL
to	NULL
3,000	NULL
bacterial	NULL
transformants	NULL
were	NULL
screened	NULL
by	NULL
a	NULL
combinatorial	NULL
method	NULL
.	NULL

In	NULL
preliminary	NULL
experiments	NULL
,	NULL
heat-killed	NULL
,	NULL
washed	NULL
bacteria	NULL
were	NULL
found	NULL
to	NULL
substitute	NULL
for	NULL
inclusion	NULL
body	NULL
preparations	NULL
of	NULL
protein	NULL
in	NULL
lymphoproliferation	NULL
assays	NULL
at	NULL
the	NULL
pool	NULL
(	NULL
5	NULL
to	NULL
12	NULL
bacterial	NULL
clones	NULL
)	NULL
and	NULL
final-assay	NULL
stages	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Sequencing	NULL
of	NULL
plasmids	NULL
in	NULL
positive	NULL
bacteria	NULL
showed	NULL
that	NULL
TCC	NULL
ESLA.9	NULL
recognized	NULL
a	NULL
44-amino-acid	NULL
fragment	NULL
of	NULL
U	NULL
,	NULL
49	NULL
gene	NULL
product	NULL
VP22	NULL
(	NULL
amino	NULL
acids	NULL
177	NULL
to	NULL
220	NULL
)	NULL
,	NULL
while	NULL
TCC	NULL
ESL2.20	NULL
recognized	NULL
a	NULL
34-amino-acid	NULL
fragment	NULL
of	NULL
the	NULL
U	NULL
,	NULL
21	NULL
gene	NULL
prod	NULL
uct	NULL
(	NULL
amino	NULL
acids	NULL
148	NULL
to	NULL
181	NULL
)	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
single	NULL
Alul	NULL
fragments	NULL
of	NULL
HSV-2	NULL
DNA	NULL
were	NULL
inserted	NULL
in	NULL
frame	NULL
and	NULL
forward	NULL
.	NULL

Peptide	NULL
mapping	NULL
revealed	NULL
that	NULL
amino	NULL
acids	NULL
187	NULL
to	NULL
206	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
stimulated	NULL
TCC	NULL
ESI4.9	NULL
.	NULL

Fusion	NULL
proteins	NULL
as	NULL
probes	NULL
of	NULL
bulk	NULL
lesion-infiltrating	NULL
T	NULL
cells	NULL
.	NULL

Newly	NULL
discovered	NULL
T-cell	NULL
antigens	NULL
were	NULL
added	NULL
to	NULL
the	NULL
panel	NULL
of	NULL
HSV	NULL
antigens	NULL
used	NULL
to	NULL
probe	NULL
bulk	NULL
cultures	NULL
of	NULL
lesion-infiltrating	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
first	NULL
available	NULL
specimens	NULL
in	NULL
our	NULL
ongoing	NULL
studies	NULL
(	NULL
19	NULL
)	NULL
were	NULL
a	NULL
set	NULL
of	NULL
four	NULL
biopsy	NULL
specimens	NULL
(	NULL
2	NULL
mm	NULL
each	NULL
)	NULL
obtained	NULL
from	NULL
a	NULL
day-5	NULL
(	NULL
virus	NULL
culture	NULL
positive	NULL
)	NULL
buttock	NULL
lesion	NULL
due	NULL
to	NULL
a	NULL
recurrence	NULL
of	NULL
HSV-2	NULL
in	NULL
patient	NULL
1	NULL
(	NULL
17	NULL
)	NULL
.	NULL

All	NULL
four	NULL
biopsy	NULL
specimens	NULL
showed	NULL
reactivity	NULL
with	NULL
VP22	NULL
105-190	NULL
but	NULL
antigen	NULL
DX32	NULL
mock	NULL
HSV-2	NULL
HSV-1	NULL
anal	NULL
me	NULL
--	NULL
26	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
HSV	NULL
viral	NULL
phenotype	NULL
of	NULL
the	NULL
U	NULL
;	NULL
49	NULL
gene	NULL
product	NULL
(	NULL
VP22	NULL
)	NULL
of	NULL
IRV	NULL
DX32	NULL
.	NULL

Lysates	NULL
of	NULL
mock-infected	NULL
cells	NULL
and	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
indicated	NULL
viral	NULL
strains	NULL
were	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
blotted	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
VP22-specific	NULL
MAb	NULL
.	NULL

The	NULL
molecular	NULL
weights	NULL
(	NULL
in	NULL
thou-sands	NULL
)	NULL
of	NULL
marker	NULL
proteins	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
right	NULL
.	NULL

voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
TABLE	NULL
1	NULL
.	NULL

Identification	NULL
of	NULL
protein	NULL
libraries	NULL
eliciting	NULL
proliferation	NULL
of	NULL
HSV-specific	NULL
TCC	NULL
``	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
mean	NULL
cpm	NULL
)	NULL
with	NULL
:	NULL
TCC	NULL
and	NULL
library	NULL
``	NULL
Control®	NULL
Stimulus	NULL
Medium	NULL
HSV-2	NULL
4.2E1	NULL
286	NULL
21,591	NULL
pUEX1-BamHI	NULL
w-Smal	NULL
10,105	NULL
pUEX2-BamHI	NULL
w-Smal	NULL
4,150	NULL
pUEX3-BamHI	NULL
w-Smal	NULL
1,903	NULL
2.3	NULL
102	NULL
11,014	NULL
pUEX1-BamHI	NULL
w-Smal	NULL
418	NULL
pUEX2-BamHI	NULL
w-Smal	NULL
785	NULL
pUEX3-BamHI	NULL
w-Smal	NULL
2,279	NULL
ESL4.9	NULL
146	NULL
66,013	NULL
pUEX1-HGS52-Smal-Alul	NULL
-52.	NULL
pUEX2-HGS52-Smal-Alul	NULL
-25	NULL
pUEX3-HGS52-Smal-Alul	NULL
16,235	NULL
ESL2.20	NULL
123	NULL
13,359	NULL
pUEX1-HGS52-Smal-Alul	NULL
1	NULL
pUEX2-HGS52-Smal-Alul	NULL
768	NULL
pUEX3-HGS52-Smal-Alul	NULL
5,427	NULL
@	NULL
Proliferation	NULL
is	NULL
expressed	NULL
as	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Autologous	NULL
EBV-LCL	NULL
(	NULL
clones	NULL
4.2E1	NULL
and	NULL
2.3	NULL
)	NULL
or	NULL
PBMC	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
,	NULL
and	NULL
library-derived	NULL
fusion	NULL
protein	NULL
antigens	NULL
were	NULL
diluted	NULL
1:300	NULL
.	NULL

®	NULL
Library	NULL
designations	NULL
consist	NULL
of	NULL
an	NULL
expression	NULL
vector	NULL
,	NULL
the	NULL
HSV-2	NULL
restriction	NULL
fragment	NULL
or	NULL
strain	NULL
of	NULL
full-length	NULL
viral	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
restriction	NULL
enzyme	NULL
(	NULL
s	NULL
)	NULL
used	NULL
to	NULL
digest	NULL
viral	NULL
DNA	NULL
.	NULL

©	NULL
Controls	NULL
consisted	NULL
of	NULL
10°	NULL
autologous	NULL
irradiated	NULL
(	NULL
3,300	NULL
rads	NULL
)	NULL
PBMC	NULL
and	NULL
either	NULL
mock-infected	NULL
cell	NULL
lysate	NULL
or	NULL
UV-treated	NULL
HSV-2	NULL
antigen	NULL
.	NULL

not	NULL
with	NULL
B-galactosidase	NULL
,	NULL
glycoprotein	NULL
B	NULL
or	NULL
D	NULL
,	NULL
or	NULL
VP16	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TCC	NULL
were	NULL
derived	NULL
after	NULL
the	NULL
original	NULL
bulk	NULL
culture	NULL
was	NULL
restimulated	NULL
for	NULL
one	NULL
cycle	NULL
with	NULL
VP22	NULL
105-190	NULL
fusion	NULL
protein	NULL
.	NULL

The	NULL
proliferative	NULL
responses	NULL
of	NULL
TCC	NULL
1.L3D5.10.8	NULL
TABLE	NULL
2	NULL
.	NULL

Antigenic	NULL
specificity	NULL
of	NULL
HSV-2-reactive	NULL
TCC	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
(	NULL
Acpm®	NULL
)	NULL
with	NULL
:	NULL
TCC	NULL
and	NULL
bacterial	NULL
clone	NULL
``	NULL
Control	NULL
antigen	NULL
``	NULL
(	NULL
viral	NULL
sequence	NULL
``	NULL
)	NULL
Recombinant	NULL
-	NULL
pUEX-antigen	NULL
derived	NULL
HSV-1	NULL
HSV-2	NULL
B-Gal	NULL
4.2E1	NULL
93	NULL
ND	NULL
ND	NULL
1.1.3	NULL
(	NULL
VP22	NULL
105-190	NULL
)	NULL
4,875	NULL
49.262.12°	NULL
(	NULL
VP22	NULL
105-190	NULL
)	NULL
6,898	NULL
2.3	NULL
231	NULL
543	NULL
53,032	NULL
3.19	NULL
(	NULL
U	NULL
,	NULL
50	NULL
118-312	NULL
)	NULL
43,971	NULL
50.583.44	NULL
(	NULL
U	NULL
,	NULL
50	NULL
118-312	NULL
)	NULL
34,453	NULL
50.397	NULL
(	NULL
U	NULL
;	NULL
,	NULL
50	NULL
118-250	NULL
)	NULL
66,501	NULL
ESL4.9	NULL
and	NULL
C11	NULL
(	NULL
VP22	NULL
177-220	NULL
)	NULL
59,400	NULL
_	NULL
166	NULL
112,803	NULL
64,685	NULL
ESL2.20	NULL
and	NULL
C9D10	NULL
(	NULL
U	NULL
,	NULL
21	NULL
148-181	NULL
)	NULL
23,543	NULL
173	NULL
0	NULL
37,989	NULL
*	NULL
Bacterially	NULL
derived	NULL
recombinant	NULL
fusion	NULL
protein	NULL
antigens	NULL
were	NULL
used	NULL
at	NULL
a	NULL
1:900	NULL
dilution	NULL
.	NULL

Autologous	NULL
EBV-LCL	NULL
(	NULL
clone	NULL
4.2E1	NULL
)	NULL
or	NULL
PBMC	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
.	NULL

*	NULL
Amino	NULL
acids	NULL
predicted	NULL
forward	NULL
and	NULL
in	NULL
frame	NULL
with	NULL
-galactosidase	NULL
from	NULL
sequence	NULL
data	NULL
.	NULL

©	NULL
Compared	NULL
to	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
medium	NULL
,	NULL
which	NULL
was	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
in	NULL
each	NULL
case	NULL
.	NULL

4	NULL
B-Gal	NULL
,	NULL
B-galactosidase	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

*	NULL
Confirmatory	NULL
subclone	NULL
of	NULL
1.1.3	NULL
,	NULL
containing	NULL
only	NULL
a	NULL
262-bp	NULL
Smel	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
49	NULL
DNA	NULL
forward	NULL
and	NULL
in	NULL
frame	NULL
with	NULL
pUEX3	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

/	NULL
Confirmatory	NULL
subclones	NULL
of	NULL
3.19	NULL
,	NULL
containing	NULL
a	NULL
583-bp	NULL
Smal	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
50	NULL
or	NULL
a	NULL
397-bp	NULL
Smal-Stul	NULL
fragment	NULL
of	NULL
U	NULL
;	NULL
50	NULL
DNA	NULL
forward	NULL
and	NULL
in	NULL
frame	NULL
with	NULL
pUEX3	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

CD4	NULL
T	NULL
CELLS	NULL
SPECIFIC	NULL
FOR	NULL
HSV-2	NULL
TEGUMENT	NULL
PROTEINS	NULL
-	NULL
7479	NULL
105-126	NULL
115-136	NULL
125-146	NULL
(	NULL
TCC	NULL
4.261	NULL
145-166	NULL
155-176	NULL
165-190	NULL
B-gal	NULL
vP22	NULL
105-190	NULL
100	NULL
1000	NULL
10000	NULL
100000	NULL
105-126	NULL
t15-136	NULL
125-146	NULL
5	NULL
135-156	NULL
=r	NULL
145-166	NULL
2	NULL
fs5-176	NULL
TCC	NULL
1.L3D5.10.8	NULL
©	NULL
165-190	NULL
B-gal	NULL
vP22	NULL
105-190	NULL
HSV-2	NULL
100	NULL
1000	NULL
10000	NULL
100000	NULL
177-196	NULL
187-206	NULL
197-216	NULL
207-220	NULL
TCC	NULL
ESL4.9	NULL
B-gal	NULL
VP22	NULL
177-220	NULL
HSV-2	NULL
100	NULL
1000	NULL
10000	NULL
100000	NULL
delta	NULL
cpm	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Proliferative	NULL
responses	NULL
of	NULL
VP22-specific	NULL
TCC	NULL
to	NULL
peptide	NULL
epitopes	NULL
in	NULL
VP22	NULL
of	NULL
HSV-2	NULL
.	NULL

APC	NULL
were	NULL
autologous	NULL
EBV-LCL	NULL
(	NULL
for	NULL
TCC	NULL
4.2E1	NULL
)	NULL
or	NULL
autologous	NULL
PBMC	NULL
(	NULL
for	NULL
other	NULL
TCC	NULL
)	NULL
.	NULL

Antigens	NULL
included	NULL
-galactosidase	NULL
and	NULL
fusion	NULL
proteins	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
and	NULL
peptides	NULL
used	NULL
at	NULL
3	NULL
M	NULL
(	NULL
for	NULL
TCC	NULL
4.2E1	NULL
)	NULL
or	NULL
1	NULL
M	NULL
(	NULL
for	NULL
other	NULL
TCC	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
Acpm	NULL
,	NULL
expressing	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
the	NULL
medium	NULL
,	NULL
which	NULL
was	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
in	NULL
each	NULL
case	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
to	NULL
VP22	NULL
105-190	NULL
and	NULL
constituent	NULL
peptides	NULL
document	NULL
a	NULL
third	NULL
T-cell	NULL
epitope	NULL
in	NULL
VP22	NULL
,	NULL
contained	NULL
within	NULL
amino	NULL
acids	NULL
125	NULL
to	NULL
146	NULL
.	NULL

Definition	NULL
of	NULL
additional	NULL
T-cell	NULL
epitopes	NULL
in	NULL
tegument	NULL
protein	NULL
VP16	NULL
.	NULL

We	NULL
previously	NULL
found	NULL
three	NULL
epitopes	NULL
within	NULL
VP16	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
,	NULL
all	NULL
HSV-2	NULL
type	NULL
specific	NULL
(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
detected	NULL
proliferative	NULL
responses	NULL
to	NULL
full-length	NULL
VP16	NULL
in	NULL
bulk	NULL
cultures	NULL
of	NULL
genital	NULL
HSV-2	NULL
lesion-infiltrating	NULL
lymphocytes	NULL
from	NULL
four	NULL
of	NULL
seven	NULL
(	NULL
57	NULL
%	NULL
)	NULL
patients	NULL
(	NULL
19	NULL
)	NULL
.	NULL

We	NULL
sought	NULL
additional	NULL
peptide	NULL
epitopes	NULL
within	NULL
VP16	NULL
by	NULL
two	NULL
strategies	NULL
.	NULL

The	NULL
first	NULL
strategy	NULL
was	NULL
to	NULL
screen	NULL
panels	NULL
of	NULL
clones	NULL
recovered	NULL
from	NULL
lesion	NULL
vesicle	NULL
fluid	NULL
for	NULL
reactivity	NULL
with	NULL
recombinant	NULL
VP16	NULL
of	NULL
HSV-2	NULL
,	NULL
followed	NULL
by	NULL
epitope	NULL
mapping	NULL
with	NULL
peptides	NULL
.	NULL

Peptides	NULL
containing	NULL
amino	NULL
acids	NULL
185	NULL
to	NULL
197	NULL
and	NULL
the	NULL
overlapping	NULL
pair	NULL
209-221	NULL
and	NULL
213-225	NULL
were	NULL
stimulatory	NULL
for	NULL
TCC	NULL
RH.13	NULL
and	NULL
KM.7	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

All	NULL
other	NULL
VP16	NULL
peptides	NULL
were	NULL
negative	NULL
(	NULL
<	NULL
500	NULL
cpm	NULL
[	NULL
data	NULL
not	NULL
The	NULL
second	NULL
strategy	NULL
involved	NULL
use	NULL
of	NULL
PBMC	NULL
as	NULL
the	NULL
starting	NULL
material	NULL
and	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
recombinant	NULL
baculovirus-derived	NULL
VP16	NULL
.	NULL

Clones	NULL
(	NULL
BM.17	NULL
and	NULL
$	NULL
B.17	NULL
)	NULL
from	NULL
two	NULL
individuals	NULL
recognized	NULL
the	NULL
same	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
437	NULL
to	NULL
449	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
B-galactosidase-VP16	NULL
fusion	NULL
protein	NULL
and	NULL
whole	NULL
virus	NULL
.	NULL

All	NULL
three	NULL
newly	NULL
defined	NULL
VP16	NULL
epitopes	NULL
were	NULL
type	NULL
com-mon	NULL
,	NULL
shared	NULL
by	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
whole-virus	NULL
preparations	NULL
,	NULL
as	NULL
expected	NULL
from	NULL
sequence	NULL
data	NULL
(	NULL
6	NULL
)	NULL
.	NULL

7480	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

TABLE	NULL
3	NULL
.	NULL

Epitopes	NULL
within	NULL
VP16	NULL
of	NULL
HSV-2	NULL
recognized	NULL
by	NULL
lesion-	NULL
and	NULL
PBMC-derived	NULL
CD4	NULL
TCC	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Acpm®	NULL
``	NULL
)	NULL
with	NULL
:	NULL
HSV-2	NULL
VP16	NULL
peptide	NULL
``	NULL
TCC	NULL
(	NULL
origin	NULL
)	NULL
Whole-virus	NULL
antigen	NULL
Recombinant	NULL
HSV-2	NULL
protein	NULL
``	NULL
HSV-1	NULL
HSV-2	NULL
VP16	NULL
1-492	NULL
B-Gal-VP16	NULL
180-492	NULL
Amino	NULL
acids	NULL
Acpm	NULL
Newly	NULL
reported	NULL
epitopes	NULL
RH.13	NULL
(	NULL
lesion	NULL
)	NULL
3,340	NULL
3,407	NULL
32,991	NULL
ND	NULL
185-197	NULL
55,614	NULL
KM.7	NULL
(	NULL
lesion	NULL
)	NULL
6,093	NULL
5,847	NULL
5,627	NULL
ND	NULL
209-221	NULL
10,075	NULL
BM.17	NULL
(	NULL
PBMC	NULL
)	NULL
30,784	NULL
13,777	NULL
ND	NULL
45,958	NULL
437-449	NULL
79,723	NULL
$	NULL
B.17	NULL
(	NULL
PBMC	NULL
)	NULL
2,207	NULL
4,187	NULL
ND	NULL
12,178	NULL
437-449	NULL
36,442	NULL
Previously	NULL
reported	NULL
epitopes	NULL
ESLA4.34	NULL
(	NULL
lesion	NULL
)	NULL
256	NULL
8,780	NULL
17,302	NULL
ND	NULL
389-401	NULL
12,968	NULL
393-405	NULL
95,942	NULL
ESL3.334	NULL
(	NULL
lesion	NULL
)	NULL
253	NULL
14,232	NULL
22,754	NULL
16,434	NULL
430-444	NULL
27,283	NULL
1A.B.25	NULL
(	NULL
lesion	NULL
)	NULL
414	NULL
33,493	NULL
24,919	NULL
41,123	NULL
431-440	NULL
38,664	NULL
@	NULL
Compared	NULL
to	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
the	NULL
medium	NULL
,	NULL
which	NULL
was	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
in	NULL
each	NULL
case	NULL
.	NULL

®	NULL
VP16	NULL
1-492	NULL
(	NULL
baculovirus-derived	NULL
)	NULL
was	NULL
used	NULL
at	NULL
1	NULL
ug/ml	NULL
.	NULL

B-Gal-VP16	NULL
180-492	NULL
was	NULL
used	NULL
at	NULL
a	NULL
1:1,000	NULL
dilution	NULL
.	NULL

B-Gal	NULL
,	NULL
B-galactosidase	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

°	NULL
Peptides	NULL
were	NULL
used	NULL
at	NULL
1	NULL
M.	NULL
HLA	NULL
restriction	NULL
.	NULL

The	NULL
HLA	NULL
restriction	NULL
of	NULL
the	NULL
TCC-recogniz-ing	NULL
antigens	NULL
encoded	NULL
near	NULL
0.7	NULL
map	NULL
units	NULL
was	NULL
determined	NULL
in	NULL
detail	NULL
.	NULL

Proliferation	NULL
of	NULL
TCC	NULL
4.2E1	NULL
,	NULL
specific	NULL
for	NULL
VP22	NULL
105-126	NULL
,	NULL
is	NULL
inhibited	NULL
84	NULL
%	NULL
by	NULL
an	NULL
anti-DP	NULL
MAb	NULL
but	NULL
less	NULL
than	NULL
20	NULL
%	NULL
by	NULL
an	NULL
anti-DR	NULL
or	NULL
anti-DQ	NULL
MAb	NULL
.	NULL

TCC	NULL
4.2E1	NULL
is	NULL
from	NULL
a	NULL
DPB1*2001/	NULL
DPB1*0402	NULL
heterozygous	NULL
donor	NULL
.	NULL

Allogeneic	NULL
EBV-LCL	NULL
bearing	NULL
DPB1*2001	NULL
but	NULL
not	NULL
DPB1*0402	NULL
present	NULL
antigen	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
,	NULL
establishing	NULL
restriction	NULL
by	NULL
DPB1*2001	NULL
.	NULL

Proliferation	NULL
of	NULL
TCC	NULL
2.3	NULL
,	NULL
specific	NULL
for	NULL
U	NULL
,	NULL
50	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
an	NULL
anti-DR	NULL
MAb	NULL
but	NULL
not	NULL
by	NULL
an	NULL
anti-DP	NULL
or	NULL
anti-DQ	NULL
MAb	NULL
.	NULL

This	NULL
clone	NULL
is	NULL
from	NULL
a	NULL
DRB1*0301/BRB1*0701	NULL
heterozygous	NULL
donor	NULL
.	NULL

Allogeneic	NULL
PBMC	NULL
from	NULL
a	NULL
DRB1*0301	NULL
donor	NULL
presented	NULL
antigen	NULL
,	NULL
consistent	NULL
with	NULL
binding	NULL
of	NULL
antigenic	NULL
peptide	NULL
to	NULL
this	NULL
allele	NULL
.	NULL

However	NULL
,	NULL
presentation	NULL
by	NULL
one	NULL
of	NULL
the	NULL
linked	NULL
DR	NULL
gene	NULL
products	NULL
DRwS52	NULL
and	NULL
DRw53	NULL
can	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
.	NULL

Additional	NULL
HLA	NULL
restriction	NULL
studies	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
5	NULL
.	NULL

The	NULL
HLA	NULL
restriction	NULL
of	NULL
TCC	NULL
BM.17	NULL
was	NULL
studied	NULL
in	NULL
detail	NULL
,	NULL
since	NULL
the	NULL
antigenic	NULL
peptide	NULL
,	NULL
VP16	NULL
437-449	NULL
,	NULL
overlaps	NULL
two	NULL
previously	NULL
described	NULL
(	NULL
18	NULL
,	NULL
21	NULL
)	NULL
VP16	NULL
epitopes	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Proliferation	NULL
of	NULL
TCC	NULL
BM.17	NULL
and	NULL
the	NULL
similar	NULL
clone	NULL
$	NULL
B.17	NULL
was	NULL
inhibited	NULL
90	NULL
%	NULL
by	NULL
an	NULL
anti-DQ	NULL
MAb	NULL
but	NULL
less	NULL
than	NULL
25	NULL
%	NULL
by	NULL
an	NULL
anti-DR	NULL
or	NULL
anti-DP	NULL
MAb	NULL
.	NULL

Donors	NULL
8	NULL
and	NULL
9	NULL
are	NULL
heterozygous	NULL
for	NULL
HLA	NULL
DQB1*0201/0501	NULL
.	NULL

At	NULL
high	NULL
concentrations	NULL
of	NULL
peptide	NULL
,	NULL
both	NULL
DQB1*0201	NULL
and	NULL
DQB1*0501	NULL
homozygous	NULL
EBV-LCL	NULL
appeared	NULL
to	NULL
present	NULL
antigen	NULL
to	NULL
TCC	NULL
BM.17	NULL
.	NULL

However	NULL
,	NULL
DQB1*0501	NULL
homozygous	NULL
cells	NULL
presented	NULL
peptide	NULL
much	NULL
more	NULL
efficiently	NULL
than	NULL
DQB1*0201	NULL
homozygous	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
three	NULL
different	NULL
but	NULL
overlapping	NULL
epitopes	NULL
in	NULL
VP16	NULL
431-449	NULL
are	NULL
presented	NULL
by	NULL
HLA	NULL
DQB1*0302	NULL
,	NULL
DQB1*0201	NULL
,	NULL
and	NULL
DQB1*0501	NULL
.	NULL

CTL	NULL
activity	NULL
of	NULL
tegument-specific	NULL
CD4	NULL
TCC	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
the	NULL
CD4	NULL
TCC	NULL
with	NULL
newly	NULL
and	NULL
previously	NULL
identified	NULL
spec-ificities	NULL
were	NULL
tested	NULL
by	NULL
using	NULL
EBV-LCL	NULL
target	NULL
cells	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
.	NULL

All	NULL
clones	NULL
tested	NULL
displayed	NULL
cytolytic	NULL
activity	NULL
towards	NULL
peptide-loaded	NULL
target	NULL
cells	NULL
.	NULL

Cytolytic	NULL
activity	NULL
against	NULL
target	NULL
cells	NULL
infected	NULL
with	NULL
HSV-2	NULL
showed	NULL
greater	NULL
variability	NULL
.	NULL

VP22-specific	NULL
TCC	NULL
4.2E1	NULL
was	NULL
active	NULL
,	NULL
while	NULL
VP22-specific	NULL
TCC	NULL
from	NULL
other	NULL
donors	NULL
were	NULL
not	NULL
.	NULL

Among	NULL
the	NULL
seven	NULL
VP16-specific	NULL
TCC	NULL
tested	NULL
,	NULL
six	NULL
displayed	NULL
greater	NULL
than	NULL
10	NULL
%	NULL
cytotoxicity	NULL
towards	NULL
HSV-2-infected	NULL
target	NULL
cells	NULL
.	NULL

The	NULL
single	NULL
U	NULL
,	NULL
21-	NULL
and	NULL
U	NULL
,	NULL
50-specific	NULL
TCC	NULL
were	NULL
not	NULL
active	NULL
against	NULL
virus-infected	NULL
target	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
HSV-specific	NULL
T	NULL
cells	NULL
selectively	NULL
infiltrate	NULL
recurrent	NULL
genital	NULL
HSV-2	NULL
lesions	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Local	NULL
CTL	NULL
activity	NULL
,	NULL
with	NULL
CD4-	NULL
and	NULL
CD8	NULL
mediated	NULL
components	NULL
,	NULL
is	NULL
correlated	NULL
with	NULL
viral	NULL
clearance	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
antigens	NULL
recognized	NULL
by	NULL
local	NULL
HSV-specific	NULL
T	NULL
cells	NULL
are	NULL
diverse	NULL
and	NULL
in	NULL
many	NULL
cases	NULL
unknown	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
document	NULL
recognition	NULL
of	NULL
tegument	NULL
proteins	NULL
VP22	NULL
and	NULL
U	NULL
,	NULL
21	NULL
and	NULL
the	NULL
viral	NULL
dUTPase	NULL
,	NULL
and	NULL
we	NULL
extend	NULL
our	NULL
previous	NULL
observations	NULL
on	NULL
tegument	NULL
protein	NULL
VP16	NULL
.	NULL

HSV	NULL
has	NULL
several	NULL
characteristics	NULL
which	NULL
facilitate	NULL
the	NULL
expression	NULL
cloning	NULL
system	NULL
described	NULL
in	NULL
this	NULL
report	NULL
.	NULL

Genomic	NULL
double-stranded	NULL
DNA	NULL
can	NULL
be	NULL
used	NULL
directly	NULL
,	NULL
since	NULL
introns	NULL
are	NULL
rare	NULL
in	NULL
the	NULL
HSV	NULL
genome	NULL
.	NULL

The	NULL
same	NULL
HSV	NULL
-2	NULL
strain	NULL
,	NULL
HG52	NULL
(	NULL
9	NULL
)	NULL
,	NULL
was	NULL
used	NULL
to	NULL
screen	NULL
candidate	NULL
lesion-derived	NULL
TCC	NULL
and	NULL
make	NULL
protein	NULL
libraries	NULL
.	NULL

The	NULL
relatively	NULL
low	NULL
degree	NULL
of	NULL
strain	NULL
variability	NULL
(	NULL
28	NULL
)	NULL
between	NULL
HSV-2	NULL
strains	NULL
in	NULL
the	NULL
donors	NULL
and	NULL
HGS52	NULL
might	NULL
rarely	NULL
lead	NULL
to	NULL
omission	NULL
of	NULL
an	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
recognized	NULL
in	NULL
vivo	NULL
;	NULL
application	NULL
to	NULL
viruses	NULL
with	NULL
more	NULL
strain	NULL
variation	NULL
would	NULL
benefit	NULL
from	NULL
the	NULL
use	NULL
of	NULL
autologous	NULL
isolates	NULL
.	NULL

Notably	NULL
,	NULL
reactivity	NULL
with	NULL
VP22	NULL
was	NULL
detected	NULL
in	NULL
two	NULL
independent	NULL
expression	NULL
cloning	NULL
experiments	NULL
with	NULL
lesion-infiltrating	NULL
TCC	NULL
from	NULL
two	NULL
donors	NULL
.	NULL

VP22	NULL
reactivity	NULL
was	NULL
also	NULL
detected	NULL
during	NULL
screening	NULL
of	NULL
the	NULL
first	NULL
available	NULL
set	NULL
of	NULL
bulk	NULL
lesion-infiltrating	NULL
lymphocyte	NULL
cultures	NULL
.	NULL

We	NULL
plan	NULL
assessment	NULL
of	NULL
the	NULL
reactivity	NULL
of	NULL
bulk	NULL
and	NULL
cloned	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
herpetic	NULL
lesions	NULL
of	NULL
additional	NULL
subjects	NULL
after	NULL
expression	NULL
of	NULL
full-length	NULL
antigens	NULL
.	NULL

Thus	NULL
far	NULL
,	NULL
10	NULL
additional	NULL
clones	NULL
from	NULL
three	NULL
patients	NULL
have	NULL
been	NULL
negative	NULL
with	NULL
fragments	NULL
of	NULL
U	NULL
;	NULL
,	NULL
49	NULL
,	NULL
U	NULL
;	NULL
21	NULL
,	NULL
and	NULL
U	NULL
,	NULL
50	NULL
discussed	NULL
in	NULL
this	NULL
report	NULL
;	NULL
assessment	NULL
of	NULL
the	NULL
relative	NULL
immunodominance	NULL
of	NULL
tegument	NULL
TABLE	NULL
4	NULL
.	NULL

Determination	NULL
of	NULL
restricting	NULL
HLA	NULL
allele	NULL
of	NULL
lesion-derived	NULL
CD4	NULL
TCC	NULL
4.2E1	NULL
and	NULL
2.3°	NULL
TCC	NULL
_	NULL
Antigen	NULL
APC	NULL
HLA	NULL
type	NULL
``	NULL
Acpm®	NULL
4.2E1	NULL
1.1.3	NULL
Autologous	NULL
EBV-LCL	NULL
-	NULL
DPB1*0402	NULL
,	NULL
2001	NULL
_	NULL
30,719	NULL
AMAI	NULL
EBV-LCL	NULL
DPB1*0402	NULL
2,732	NULL
ARENT	NULL
EBV-LCL	NULL
DPB1*2001	NULL
26,218	NULL
2.3	NULL
50.583.44	NULL
-	NULL
Autologous	NULL
PBMC	NULL
DRB1*0301	NULL
,	NULL
0701	NULL
_	NULL
8,964	NULL
Allogeneic	NULL
PBMC	NULL
A	NULL
Allogeneic	NULL
PBMC	NULL
B	NULL
DRB1*0701	NULL
,	NULL
1001	NULL
45	NULL
DRB1*0301	NULL
,	NULL
1301	NULL
-	NULL
19,223	NULL
``	NULL
Antigens	NULL
were	NULL
B-galactosidase	NULL
fusion	NULL
proteins	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
at	NULL
a	NULL
1:900	NULL
deletion	NULL
.	NULL

``	NULL
HLA	NULL
type	NULL
at	NULL
the	NULL
HLA	NULL
class	NULL
II	NULL
locus	NULL
as	NULL
determined	NULL
by	NULL
inhibition	NULL
with	NULL
MAb	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

°	NULL
In	NULL
comparison	NULL
to	NULL
pUEX2	NULL
control	NULL
protein	NULL
(	NULL
1:1,000	NULL
dilution	NULL
)	NULL
with	NULL
the	NULL
same	NULL
APC	NULL
,	NULL
which	NULL
caused	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
of	NULL
incorporation	NULL
in	NULL
each	NULL
case	NULL
.	NULL

Vou	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
CD4	NULL
T	NULL
CELLS	NULL
SPECIFIC	NULL
FOR	NULL
HSV-2	NULL
TEGUMENT	NULL
PROTEINS	NULL
-	NULL
7481	NULL
ing	NULL
of	NULL
dUTPase	NULL
antigen	NULL
from	NULL
infected-cell	NULL
debris	NULL
.	NULL

Lysis	NULL
of	NULL
HSV	NULL
-infected	NULL
cells	NULL
by	NULL
dUTPase-specific	NULL
TCC	NULL
4.2E1	NULL
indicates	NULL
that	NULL
,	NULL
at	NULL
least	NULL
in	NULL
vitro	NULL
,	NULL
presentation	NULL
of	NULL
endogenous	NULL
antigen	NULL
can	NULL
occur	NULL
.	NULL

Immune	NULL
responses	NULL
to	NULL
VP22	NULL
may	NULL
be	NULL
an	NULL
obstacle	NULL
to	NULL
its	NULL
use	NULL
for	NULL
delivery	NULL
of	NULL
exogenous	NULL
materials	NULL
(	NULL
30	NULL
)	NULL
in	NULL
vivo	NULL
.	NULL

Conversely	NULL
,	NULL
since	NULL
polypeptides	NULL
expressed	NULL
as	NULL
C-terminal	NULL
fusions	NULL
to	NULL
VP22	NULL
can	NULL
be	NULL
cotransported	NULL
into	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
proteins	NULL
as	NULL
VP22	NULL
fusions	NULL
may	NULL
be	NULL
of	NULL
interest	NULL
as	NULL
a	NULL
type	NULL
of	NULL
adjuvant	NULL
preparation	NULL
.	NULL

This	NULL
hypothesis	NULL
can	NULL
be	NULL
tested	NULL
by	NULL
expression	NULL
of	NULL
heterologous	NULL
epitopes	NULL
in	NULL
VP22	NULL
.	NULL

VP16	NULL
and	NULL
VP22	NULL
of	NULL
HSV-1	NULL
are	NULL
strongly	NULL
,	NULL
noncovalently	NULL
associated	NULL
in	NULL
infected	NULL
cells	NULL
as	NULL
shown	NULL
by	NULL
coimmunoprecipi-tation	NULL
.	NULL

These	NULL
proteins	NULL
colocalize	NULL
in	NULL
the	NULL
perinuclear	NULL
areas	NULL
of	NULL
cells	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Possibly	NULL
,	NULL
this	NULL
association	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
stimulating	NULL
the	NULL
apparently	NULL
high	NULL
level	NULL
of	NULL
CD4	NULL
T-cell	NULL
response	NULL
to	NULL
VP16	NULL
.	NULL

All	NULL
of	NULL
the	NULL
lesion-derived	NULL
tegument-specific	NULL
CD4	NULL
TCC	NULL
studied	NULL
had	NULL
cytolytic	NULL
potential	NULL
against	NULL
maximally	NULL
sensitized	NULL
(	NULL
pep-tide-loaded	NULL
)	NULL
target	NULL
cells	NULL
.	NULL

Why	NULL
do	NULL
only	NULL
some	NULL
clones	NULL
kill	NULL
virus-infected	NULL
cells	NULL
?	NULL

Possibly	NULL
,	NULL
some	NULL
epitopes	NULL
are	NULL
not	NULL
presented	NULL
in	NULL
infected	NULL
APC	NULL
,	NULL
and	NULL
some	NULL
may	NULL
be	NULL
processed	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
,	NULL
below	NULL
a	NULL
threshold	NULL
needed	NULL
to	NULL
trigger	NULL
a	NULL
cytolytic	NULL
response	NULL
.	NULL

Thus	NULL
far	NULL
,	NULL
with	NULL
our	NULL
small	NULL
number	NULL
of	NULL
clones	NULL
,	NULL
we	NULL
have	NULL
not	NULL
observed	NULL
a	NULL
consistent	NULL
relationship	NULL
between	NULL
antigenic	NULL
specificity	NULL
or	NULL
HLA	NULL
restricting	NULL
locus	NULL
and	NULL
sensitization	NULL
,	NULL
by	NULL
viral	NULL
infection	NULL
,	NULL
to	NULL
lysis	NULL
by	NULL
CD4	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
expression	NULL
cloning	NULL
has	NULL
allowed	NULL
the	NULL
discovery	NULL
of	NULL
novel	NULL
HSV	NULL
T-cell	NULL
antigens	NULL
.	NULL

The	NULL
in	NULL
situ	NULL
enrichment	NULL
of	NULL
antigen-specific	NULL
CD4	NULL
T	NULL
cells	NULL
in	NULL
lesions	NULL
allows	NULL
study	NULL
of	NULL
the	NULL
antigenic	NULL
repertoire	NULL
unbiased	NULL
by	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
antigen	NULL
.	NULL

The	NULL
favorable	NULL
characteristics	NULL
of	NULL
the	NULL
HSV	NULL
genome	NULL
allow	NULL
direct	NULL
use	NULL
of	NULL
libraries	NULL
of	NULL
whole-virus	NULL
DNA	NULL
.	NULL

In	NULL
the	NULL
future	NULL
,	NULL
a	NULL
more	NULL
complete	NULL
description	NULL
of	NULL
the	NULL
diversity	NULL
and	NULL
targets	NULL
of	NULL
HSV	NULL
-specific	NULL
T	NULL
105	NULL
10+	NULL
{	NULL
delta	NULL
CPM	NULL
103	NULL
4	NULL
102	NULL
A	NULL
107	NULL
10°	NULL
102	NULL
10°	NULL
[	NULL
437-449	NULL
]	NULL
LM	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

HLA	NULL
restriction	NULL
element	NULL
for	NULL
TCC	NULL
BM.17	NULL
response	NULL
to	NULL
peptide	NULL
437-449	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
.	NULL

Proliferative	NULL
responses	NULL
are	NULL
plotted	NULL
against	NULL
concentrations	NULL
of	NULL
viral	NULL
peptide	NULL
.	NULL

APC	NULL
are	NULL
EBV-LCL	NULL
that	NULL
are	NULL
either	NULL
autologous	NULL
(	NULL
solid	NULL
circles	NULL
)	NULL
,	NULL
homozygous	NULL
for	NULL
HLA	NULL
DQB1*0501	NULL
(	NULL
open	NULL
inverted	NULL
triangles	NULL
)	NULL
,	NULL
or	NULL
homozygous	NULL
for	NULL
HLA	NULL
DQB1*0201	NULL
(	NULL
solid	NULL
squares	NULL
)	NULL
.	NULL

specific	NULL
responses	NULL
in	NULL
comparison	NULL
to	NULL
HSV	NULL
glycoproteins	NULL
is	NULL
not	NULL
possible	NULL
at	NULL
this	NULL
time	NULL
.	NULL

Tegument	NULL
antigens	NULL
may	NULL
be	NULL
suitable	NULL
targets	NULL
for	NULL
lesion-infiltrating	NULL
CD4	NULL
T	NULL
cells	NULL
because	NULL
of	NULL
their	NULL
abundance	NULL
.	NULL

VP16	NULL
and	NULL
VP22	NULL
are	NULL
present	NULL
in	NULL
large	NULL
amounts	NULL
:	NULL
on	NULL
the	NULL
order	NULL
of	NULL
1.6	NULL
x	NULL
10°	NULL
molecules	NULL
of	NULL
VP16	NULL
(	NULL
45	NULL
)	NULL
and	NULL
2.5	NULL
x	NULL
10°	NULL
to	NULL
2.8	NULL
x	NULL
10°	NULL
molecules	NULL
of	NULL
VP22	NULL
(	NULL
23	NULL
)	NULL
are	NULL
incorporated	NULL
into	NULL
each	NULL
virion	NULL
in	NULL
HSV-1	NULL
.	NULL

Less	NULL
information	NULL
is	NULL
available	NULL
for	NULL
U	NULL
,	NULL
21	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

The	NULL
viral	NULL
dUTPase	NULL
is	NULL
the	NULL
first	NULL
nonvirion	NULL
component	NULL
documented	NULL
to	NULL
be	NULL
a	NULL
target	NULL
of	NULL
the	NULL
HSV	NULL
-specific	NULL
CD4	NULL
T-cell	NULL
response	NULL
;	NULL
no	NULL
information	NULL
is	NULL
available	NULL
concerning	NULL
its	NULL
relative	NULL
abundance	NULL
.	NULL

This	NULL
enzyme	NULL
,	NULL
like	NULL
VP16	NULL
and	NULL
VP22	NULL
,	NULL
localizes	NULL
to	NULL
the	NULL
nuclei	NULL
of	NULL
cells	NULL
infected	NULL
with	NULL
HSV-2	NULL
(	NULL
but	NULL
not	NULL
HSV-1	NULL
)	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Antigen	NULL
presentation	NULL
in	NULL
vivo	NULL
may	NULL
occur	NULL
after	NULL
endogenous	NULL
synthesis	NULL
of	NULL
dUTPase	NULL
in	NULL
infected	NULL
cells	NULL
or	NULL
scaveng-	NULL
cells	NULL
and	NULL
correlation	NULL
of	NULL
these	NULL
factors	NULL
with	NULL
the	NULL
duration	NULL
,	NULL
clinical	NULL
severity	NULL
,	NULL
or	NULL
complications	NULL
of	NULL
HSV	NULL
infections	NULL
,	NULL
such	NULL
as	NULL
HSV	NULL
ker-atitis	NULL
,	NULL
may	NULL
be	NULL
assisted	NULL
by	NULL
application	NULL
of	NULL
the	NULL
methods	NULL
in	NULL
this	NULL
report	NULL
.	NULL

Tegument	NULL
proteins	NULL
are	NULL
candidates	NULL
,	NULL
together	NULL
with	NULL
mem-	NULL
TABLE	NULL
5	NULL
.	NULL

Cytolytic	NULL
activity	NULL
of	NULL
lesion-derived	NULL
,	NULL
tegument-specific	NULL
CD4	NULL
TCC	NULL
,	NULL
with	NULL
summary	NULL
of	NULL
fine	NULL
specificity	NULL
and	NULL
HLA	NULL
restriction	NULL
%	NULL
Specific	NULL
release®	NULL
with	NULL
the	NULL
following	NULL
cytolysis	NULL
assay	NULL
target	NULL
:	NULL
TCC	NULL
Specificity	NULL
``	NULL
HLA	NULL
b	NULL
restriction	NULL
'	NULL
Auto	NULL
HSV-2	NULL
_	NULL
Auto	NULL
peptide	NULL
-	NULL
Auto	NULL
mock	NULL
-	NULL
Allo	NULL
HSV-2	NULL
_	NULL
Allo	NULL
peptide	NULL
-	NULL
Allo	NULL
mock	NULL
Newly	NULL
reported	NULL
epitopes	NULL
4.2E1	NULL
VP22	NULL
105-126	NULL
-	NULL
DPB1*2001	NULL
20.7	NULL
44.2	NULL
-4.1	NULL
-2.9	NULL
-1.7	NULL
4.6	NULL
ESL4.9	NULL
VP22	NULL
187-206	NULL
-	NULL
DR	NULL
``	NULL
-0.6	NULL
20.2	NULL
1.3	NULL
0	NULL
0	NULL
0	NULL
ESL2.20	NULL
U	NULL
,	NULL
21	NULL
148-181	NULL
-	NULL
DR	NULL
``	NULL
2.7	NULL
NA	NULL
0.9	NULL
0	NULL
NA	NULL
0	NULL
1.L3D5.10.8	NULL
VP22	NULL
125-146	NULL
-	NULL
DR°	NULL
1.1	NULL
61.1	NULL
-0.3	NULL
-0.4	NULL
-0.6	NULL
-0.4	NULL
1.L3D5.10.12	NULL
VP22	NULL
125-146	NULL
-	NULL
DR°	NULL
2.5	NULL
57.6	NULL
1.6	NULL
-O0.1	NULL
-2.5	NULL
-1.4	NULL
RH.13	NULL
VP16	NULL
185-197	NULL
-	NULL
DR4	NULL
62.5	NULL
55.2	NULL
-0.9	NULL
9.6	NULL
0.3	NULL
1.8	NULL
KM.7	NULL
VP16	NULL
209-221	NULL
-	NULL
DR2	NULL
38.7	NULL
43.6	NULL
2.7	NULL
-2.2	NULL
4.3	NULL
-1.1	NULL
BM.17	NULL
VP16	NULL
437-449	NULL
-	NULL
DQB1*0501	NULL
10.1	NULL
28.5	NULL
-0.3	NULL
ND	NULL
ND	NULL
ND	NULL
$	NULL
B.17	NULL
VP16	NULL
437-449	NULL
-	NULL
DQB1*0501	NULL
48.7	NULL
60.6	NULL
5.4	NULL
ND	NULL
ND	NULL
ND	NULL
2.3	NULL
U	NULL
,	NULL
,	NULL
50	NULL
118-250	NULL
-	NULL
DRB1*0301	NULL
0.8	NULL
NA	NULL
0	NULL
1.1	NULL
NA	NULL
0	NULL
Previously	NULL
described	NULL
epitopes	NULL
ESLA4.34	NULL
VP16	NULL
393-405	NULL
-	NULL
DRB1*0402	NULL
2.1	NULL
10.4	NULL
1.0	NULL
0.5	NULL
0.6	NULL
0.3	NULL
ESL3.334	NULL
VP16	NULL
430-444	NULL
-	NULL
DQB1*0302	NULL
12.3	NULL
33.6	NULL
0.7	NULL
1.4	NULL
0.3	NULL
2.2	NULL
1A.B.25	NULL
VP16	NULL
431-440	NULL
-	NULL
DQB1*0201	NULL
24.3	NULL
42.2	NULL
1.9	NULL
1.7	NULL
2.1	NULL
-0.4	NULL
``	NULL
Indicates	NULL
peptide	NULL
used	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
to	NULL
load	NULL
targets	NULL
in	NULL
CTL	NULL
assay	NULL
for	NULL
selected	NULL
TCC	NULL
.	NULL

*	NULL
Maximum	NULL
extent	NULL
of	NULL
definition	NULL
of	NULL
HLA	NULL
restricting	NULL
locus	NULL
and/or	NULL
allele	NULL
.	NULL

Subjects	NULL
6	NULL
and	NULL
7	NULL
were	NULL
typed	NULL
serologically	NULL
;	NULL
others	NULL
were	NULL
typed	NULL
at	NULL
the	NULL
DNA	NULL
level	NULL
.	NULL

°	NULL
At	NULL
an	NULL
effector-to-target	NULL
ratio	NULL
of	NULL
20:1	NULL
,	NULL
except	NULL
for	NULL
ESLA4.34	NULL
(	NULL
10:1	NULL
)	NULL
.	NULL

Auto	NULL
,	NULL
autologous	NULL
EBV-LCL	NULL
as	NULL
target	NULL
cells	NULL
;	NULL
allo	NULL
,	NULL
allogeneic	NULL
EBV-LCL	NULL
mismatched	NULL
at	NULL
the	NULL
relevant	NULL
HLA	NULL
locus	NULL
(	NULL
if	NULL
known	NULL
)	NULL
or	NULL
mismatched	NULL
at	NULL
HLA-DR	NULL
and	NULL
-DQ	NULL
.	NULL

NA	NULL
,	NULL
not	NULL
available	NULL
,	NULL
since	NULL
epitope	NULL
mapping	NULL
was	NULL
not	NULL
done	NULL
and	NULL
synthetic	NULL
antigenic	NULL
peptide	NULL
was	NULL
not	NULL
made	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

``	NULL
Subject	NULL
is	NULL
heterozygous	NULL
for	NULL
HLA	NULL
DRB1*0402	NULL
and	NULL
DRB1*1301	NULL
,	NULL
and	NULL
restricting	NULL
allele	NULL
has	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

*	NULL
Subject	NULL
is	NULL
heterozygous	NULL
for	NULL
HLA	NULL
DRB1*0301	NULL
and	NULL
DRB1*1102	NULL
,	NULL
and	NULL
restricting	NULL
allele	NULL
has	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

7482	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

brane	NULL
glycoproteins	NULL
,	NULL
for	NULL
evaluation	NULL
as	NULL
possible	NULL
HSV	NULL
vaccines	NULL
in	NULL
humans	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
study	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grants	NULL
AI34616	NULL
and	NULL
CA70017	NULL
(	NULL
to	NULL
DMK	NULL
)	NULL
.	NULL

HLA	NULL
typing	NULL
was	NULL
performed	NULL
by	NULL
John	NULL
Hansen	NULL
and	NULL
Effie	NULL
Petersdorf	NULL
.	NULL

HSV-1	NULL
X	NULL
HSV-2	NULL
IRV	NULL
were	NULL
graciously	NULL
provided	NULL
by	NULL
Bernard	NULL
Roizman	NULL
(	NULL
RS1G31	NULL
)	NULL
,	NULL
Howard	NULL
Marsden	NULL
(	NULL
DX32	NULL
)	NULL
,	NULL
and	NULL
Steve	NULL
Triezenberg	NULL
(	NULL
RP-2	NULL
)	NULL
.	NULL

The	NULL
HSV-2	NULL
HGS2	NULL
BgilI	NULL
i	NULL
fragment	NULL
was	NULL
provided	NULL
by	NULL
Steve	NULL
Triezenberg	NULL
and	NULL
originally	NULL
by	NULL
Chris	NULL
Preston	NULL
.	NULL

MAb	NULL
p43	NULL
,	NULL
specific	NULL
for	NULL
VP22	NULL
,	NULL
was	NULL
provided	NULL
by	NULL
David	NULL
Meredith	NULL
.	NULL

John	NULL
C.	NULL
Hutton	NULL
provided	NULL
pUEX	NULL
vectors	NULL
,	NULL
primer	NULL
sequences	NULL
,	NULL
and	NULL
valuable	NULL
advice	NULL
.	NULL

Peptides	NULL
and	NULL
recombinant	NULL
VP16	NULL
,	NULL
gB2	NULL
,	NULL
and	NULL
gD2	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Rae	NULL
L.	NULL
Burke	NULL
and	NULL
Michael	NULL
Tigges	NULL
,	NULL
Chiron	NULL
Corporation	NULL
.	NULL

Lawrence	NULL
Corey	NULL
provided	NULL
invaluable	NULL
support	NULL
and	NULL
advice	NULL
over	NULL
several	NULL
years	NULL
.	NULL

We	NULL
thank	NULL
Jeffrey	NULL
Vieira	NULL
for	NULL
valuable	NULL
advice	NULL
and	NULL
Mike	NULL
Remington	NULL
,	NULL
Gail	NULL
R.	NULL
Barnum	NULL
,	NULL
and	NULL
Mary	NULL
Shaughnessy	NULL
for	NULL
assistance	NULL
with	NULL
specimen	NULL
collection	NULL
.	NULL

1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

REFERENCES	NULL
Ashley	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
J.	NULL
Militoni	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
A.	NULL
Nahmias	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1988	NULL
.	NULL

Comparison	NULL
of	NULL
Western	NULL
blot	NULL
(	NULL
immunoblot	NULL
)	NULL
and	NULL
glycoprotein	NULL
G-specific	NULL
immunoblot	NULL
for	NULL
detecting	NULL
antibodies	NULL
to	NULL
herpes	NULL
simplex	NULL
types	NULL
1	NULL
and	NULL
2	NULL
in	NULL
human	NULL
sera	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

26:662-667.	NULL
.	NULL

Baines	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
A.	NULL
H.	NULL
Koyama	NULL
,	NULL
T.	NULL
Huang	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
U	NULL
;	NULL
21	NULL
gene	NULL
products	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
1	NULL
are	NULL
dispensable	NULL
for	NULL
growth	NULL
in	NULL
cultured	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2929-2936.	NULL
.	NULL

Blaho	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
C.	NULL
Mitchell	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
,	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
amino	NULL
acid	NULL
sequence	NULL
shared	NULL
by	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
1	NULL
a	NULL
regulatory	NULL
proteins	NULL
0	NULL
,	NULL
4	NULL
,	NULL
22	NULL
,	NULL
and	NULL
27	NULL
predicts	NULL
the	NULL
nucleotidylation	NULL
of	NULL
the	NULL
UL21	NULL
,	NULL
UL31	NULL
,	NULL
UL47	NULL
,	NULL
and	NULL
ULA9	NULL
gene	NULL
products	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:17401-17410.	NULL
.	NULL

Bodmer	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
S.	NULL
G.	NULL
Marsh	NULL
,	NULL
E.	NULL
D.	NULL
Albert	NULL
,	NULL
W.	NULL
F.	NULL
Bodmer	NULL
,	NULL
R.	NULL
E.	NULL
Bonthrop	NULL
,	NULL
D.	NULL
Charron	NULL
,	NULL
B.	NULL
Dupont	NULL
,	NULL
H.	NULL
A.	NULL
Erlich	NULL
,	NULL
R.	NULL
Fauchet	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
A.	NULL
Svej-gaard	NULL
,	NULL
and	NULL
P.	NULL
I.	NULL
Terasaki	NULL
.	NULL

1997	NULL
.	NULL

Nomenclature	NULL
for	NULL
factor	NULL
of	NULL
the	NULL
HLA	NULL
system	NULL
,	NULL
1996	NULL
.	NULL

Tissue	NULL
Antigens	NULL
49:297-321.	NULL
.	NULL

Bressan	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
K.	NULL
K.	NULL
Stanley	NULL
.	NULL

1987.	NULL
pUEX	NULL
,	NULL
a	NULL
bacterial	NULL
expression	NULL
vector	NULL
related	NULL
to	NULL
pEX	NULL
with	NULL
universal	NULL
host	NULL
specificity	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
:	NULL
10056.	NULL
.	NULL

Cress	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Triezenberg	NULL
.	NULL

1991	NULL
.	NULL

Nucleotide	NULL
and	NULL
deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
virion	NULL
protein	NULL
16	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Gene	NULL
103:235-238.	NULL
.	NULL

Cunningham	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Merigan	NULL
.	NULL

1984	NULL
.	NULL

Leu-3+	NULL
T	NULL
cells	NULL
produce	NULL
gamma-interferon	NULL
in	NULL
patients	NULL
with	NULL
recurrent	NULL
herpes	NULL
labialis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

132	NULL
;	NULL
197-202.	NULL
.	NULL

Doherty	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
D.	NULL
M.	NULL
Koelle	NULL
,	NULL
W.	NULL
W.	NULL
Kwok	NULL
,	NULL
S.	NULL
Masewicz	NULL
,	NULL
M.	NULL
E.	NULL
Domeier	NULL
,	NULL
and	NULL
G.	NULL
T.	NULL
Nepom	NULL
.	NULL

1996	NULL
.	NULL

Allelic	NULL
variants	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
can	NULL
act	NULL
as	NULL
partial	NULL
agonists	NULL
of	NULL
antigen	NULL
specific	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

47:149.	NULL
.	NULL

Dolan	NULL
,	NULL
A.	NULL
,	NULL
F.	NULL
E.	NULL
Jamieson	NULL
,	NULL
C.	NULL
Cunningham	NULL
,	NULL
B.	NULL
C.	NULL
Barnett	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Mc-	NULL
Geoch	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
genome	NULL
sequence	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:2010-2021	NULL
.	NULL

Elliott	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Mouzakitis	NULL
,	NULL
and	NULL
P.	NULL
O'Hare	NULL
.	NULL

1995	NULL
.	NULL

VP16	NULL
interacts	NULL
via	NULL
its	NULL
activation	NULL
domain	NULL
with	NULL
VP22	NULL
,	NULL
a	NULL
tegument	NULL
protein	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
,	NULL
and	NULL
is	NULL
relocated	NULL
to	NULL
a	NULL
novel	NULL
macromolecular	NULL
assembly	NULL
in	NULL
coexpressing	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:7932-7941	NULL
.	NULL

Elliott	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Meredith	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
tegument	NULL
protein	NULL
VP22	NULL
is	NULL
encoded	NULL
by	NULL
gene	NULL
ULA9	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

73:723-736	NULL
.	NULL

Gignac	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
S.	NULL
Brauer	NULL
,	NULL
B.	NULL
Hane	NULL
,	NULL
H.	NULL
Quentmeier	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Drexler	NULL
.	NULL

1991	NULL
.	NULL

Elimination	NULL
of	NULL
mycoplasma	NULL
from	NULL
infected	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Leukemia	NULL
5	NULL
:	NULL
162-165	NULL
.	NULL

Ho	NULL
,	NULL
M.	NULL
1990	NULL
.	NULL

Interferon	NULL
as	NULL
an	NULL
agent	NULL
against	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

J.	NULL
Investig	NULL
.	NULL

Dermatol	NULL
.	NULL

95:158§5-1608	NULL
.	NULL

Jerome	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
J.	NULL
F.	NULL
Tait	NULL
,	NULL
D.	NULL
M.	NULL
Koelle	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1998	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
renders	NULL
infected	NULL
cells	NULL
resistant	NULL
to	NULL
cytotoxic	NULL
T-lymphocyte-in-duced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:436-441	NULL
.	NULL

Kit	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Kit	NULL
,	NULL
H.	NULL
Qavi	NULL
,	NULL
D.	NULL
Trkula	NULL
,	NULL
and	NULL
H.	NULL
Otsuka	NULL
.	NULL

1983	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
HSV-2	NULL
)	NULL
thymidine	NULL
kinase	NULL
gene	NULL
and	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
thymidine	NULL
kinase	NULL
polypeptide	NULL
and	NULL
its	NULL
comparison	NULL
with	NULL
the	NULL
HSV-1	NULL
thymidine	NULL
kinase	NULL
gene	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
741:158-170	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
H.	NULL
Abbo	NULL
,	NULL
A.	NULL
Peck	NULL
,	NULL
K.	NULL
Ziegweid	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1994	NULL
.	NULL

Direct	NULL
recovery	NULL
of	NULL
HSV-specific	NULL
T	NULL
lymphocyte	NULL
clones	NULL
from	NULL
human	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

169:956-961	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
L.	NULL
Corey	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
R.	NULL
J.	NULL
Eisenberg	NULL
,	NULL
G.	NULL
H.	NULL
Cohen	NULL
,	NULL
R.	NULL
Pichyangkura	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Triezenberg	NULL
.	NULL

1994	NULL
.	NULL

Antigenic	NULL
specificity	NULL
of	NULL
human	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
recovered	NULL
from	NULL
recurrent	NULL
genital	NULL
HSV-2	NULL
lesions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2803-2810	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
L.	NULL
Johnson	NULL
,	NULL
A.	NULL
N.	NULL
Ekstrom	NULL
,	NULL
P.	NULL
Byers	NULL
,	NULL
and	NULL
W.	NULL
W.	NULL
Kwok	NULL
.	NULL

1997	NULL
.	NULL

Preferential	NULL
presentation	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
T-cell	NULL
antigen	NULL
by	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

HLA	NULL
DQA1*0501/DQB1*0201	NULL
in	NULL
comparison	NULL
to	NULL
HLA	NULL
DQA1*0201/	NULL
DQB1*0201	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

53:195-205	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
C.	NULL
M.	NULL
Posavad	NULL
,	NULL
G.	NULL
R.	NULL
Barnum	NULL
,	NULL
M.	NULL
L.	NULL
Johnson	NULL
,	NULL
J.	NULL
M.	NULL
Frank	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1998	NULL
.	NULL

Clearance	NULL
of	NULL
HSV-2	NULL
from	NULL
recurrent	NULL
genital	NULL
lesions	NULL
correlates	NULL
with	NULL
infiltration	NULL
of	NULL
HSV-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

101:1500-1509	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
A.	NULL
Tigges	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
F.	NULL
W.	NULL
Symington	NULL
,	NULL
S.	NULL
R.	NULL
Riddell	NULL
,	NULL
H.	NULL
Abbo	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1993	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
infection	NULL
of	NULL
human	NULL
fibro-blasts	NULL
and	NULL
keratinocytes	NULL
inhibits	NULL
recognition	NULL
by	NULL
cloned	NULL
CD8+	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91:961-968	NULL
.	NULL

Kwok	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
M.	NULL
E.	NULL
Domeier	NULL
,	NULL
M.	NULL
L.	NULL
Joh	NULL
,	NULL
G.	NULL
T.	NULL
Nepom	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Koelle	NULL
.	NULL

1996	NULL
.	NULL

HLA-DQB	NULL
codon	NULL
57	NULL
is	NULL
a	NULL
critical	NULL
determinant	NULL
of	NULL
peptide	NULL
binding	NULL
and	NULL
recognition	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:1253-1258	NULL
.	NULL

Langenberg	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
S.	NULL
F.	NULL
Adair	NULL
,	NULL
R.	NULL
Sekulovich	NULL
,	NULL
M.	NULL
Tigges	NULL
,	NULL
C.	NULL
L.	NULL
Dekker	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
recombinant	NULL
glycoprotein	NULL
vaccine	NULL
for	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
:	NULL
safety	NULL
and	NULL
immunogenicity	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

122:889-898	NULL
.	NULL

Leslie	NULL
,	NULL
J.	NULL
,	NULL
F.	NULL
J.	NULL
Rixon	NULL
,	NULL
and	NULL
J.	NULL
McLauchlan	NULL
.	NULL

1996	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
tegument	NULL
protein	NULL
VP22	NULL
increases	NULL
its	NULL
incorporation	NULL
into	NULL
virus	NULL
particles	NULL
.	NULL

Virology	NULL
220:60-68	NULL
.	NULL

Maitland	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
I.	NULL
W.	NULL
Smith	NULL
,	NULL
J.	NULL
F.	NULL
Peutherer	NULL
,	NULL
D.	NULL
H.	NULL
H.	NULL
Robertson	NULL
,	NULL
and	NULL
K.	NULL
W.	NULL
Jones	NULL
.	NULL

1982	NULL
.	NULL

Restriction	NULL
endonuclease	NULL
analysis	NULL
of	NULL
DNA	NULL
from	NULL
genital	NULL
isolates	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

38:834-842.	NULL
.	NULL

Mickelson	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Smith	NULL
,	NULL
S.	NULL
McKinney	NULL
,	NULL
G.	NULL
Anderson	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Hansen	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
comparative	NULL
study	NULL
of	NULL
HLA-DRBI1	NULL
typing	NULL
by	NULL
standard	NULL
serology	NULL
and	NULL
hybridization	NULL
of	NULL
non-radioactive	NULL
sequence-specific	NULL
oligonucleotide	NULL
probes	NULL
to	NULL
PCR-amplified	NULL
DNA	NULL
.	NULL

Tissue	NULL
Antigens	NULL
41:86-93	NULL
.	NULL

Mikloska	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
Cunningham	NULL
.	NULL

1998	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
glycoproteins	NULL
gB	NULL
,	NULL
gC	NULL
,	NULL
and	NULL
gD	NULL
are	NULL
major	NULL
targets	NULL
for	NULL
CD4	NULL
T-lymphocyte	NULL
cytotoxicity	NULL
in	NULL
HLA-DR	NULL
expressing	NULL
human	NULL
epidermal	NULL
keratinocytes	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

79:353-361	NULL
.	NULL

Neophytou	NULL
,	NULL
P.	NULL
I.	NULL
,	NULL
B.	NULL
O.	NULL
Roep	NULL
,	NULL
S.	NULL
D.	NULL
Arden	NULL
,	NULL
E.	NULL
M.	NULL
Muir	NULL
,	NULL
G.	NULL
Duinkerken	NULL
,	NULL
A.	NULL
Kallan	NULL
,	NULL
R.	NULL
R.	NULL
de	NULL
Vries	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Hutton	NULL
.	NULL

1996	NULL
.	NULL

T-cell	NULL
epitope	NULL
analysis	NULL
using	NULL
subtracted	NULL
expression	NULL
libraries	NULL
(	NULL
TEASEL	NULL
)	NULL
:	NULL
application	NULL
to	NULL
a	NULL
38	NULL
kDa	NULL
autoan-tigen	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
from	NULL
an	NULL
insulin-dependent	NULL
diabetic	NULL
patient	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:2014-2018	NULL
.	NULL

Novotny	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
M.	NULL
L.	NULL
Parish	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Spear	NULL
.	NULL

1996	NULL
.	NULL

Variability	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
1	NULL
gL	NULL
and	NULL
anti-gL	NULL
antibodies	NULL
that	NULL
inhibit	NULL
cell	NULL
fusion	NULL
but	NULL
not	NULL
viral	NULL
infectivity	NULL
.	NULL

Virology	NULL
221:1-13	NULL
.	NULL

Para	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
K.	NULL
M.	NULL
Zezulak	NULL
,	NULL
A.	NULL
J.	NULL
Conley	NULL
,	NULL
M.	NULL
Weinberger	NULL
,	NULL
K.	NULL
Snitzer	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Spear	NULL
.	NULL

1983	NULL
.	NULL

Use	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
two	NULL
75,000-molec-ular-weight	NULL
glycoproteins	NULL
specified	NULL
by	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
in	NULL
glycoprotein	NULL
identification	NULL
and	NULL
gene	NULL
mapping	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

45:1223-1227	NULL
.	NULL

Phelan	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Elliott	NULL
,	NULL
and	NULL
P.	NULL
O'Hare	NULL
.	NULL

1998	NULL
.	NULL

Intercellular	NULL
delivery	NULL
of	NULL
the	NULL
complete	NULL
P53	NULL
protein	NULL
by	NULL
VP22	NULL
.	NULL

Natl	NULL
.	NULL

Biotechnol	NULL
.	NULL

16:440-443	NULL
.	NULL

Preston	NULL
,	NULL
V.	NULL
G.	NULL
,	NULL
A.	NULL
J.	NULL
Davison	NULL
,	NULL
H.	NULL
S.	NULL
Marsden	NULL
,	NULL
M.	NULL
C.	NULL
Timbury	NULL
,	NULL
J.	NULL
H.	NULL
Subak-Sharpe	NULL
,	NULL
and	NULL
N.	NULL
M.	NULL
Wilkie	NULL
.	NULL

1978	NULL
.	NULL

Recombinants	NULL
between	NULL
herpes	NULL
simplex	NULL
virus	NULL
types	NULL
1	NULL
and	NULL
2	NULL
:	NULL
analyses	NULL
of	NULL
genome	NULL
structures	NULL
and	NULL
expression	NULL
of	NULL
immediate-carly	NULL
polypeptides	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

28:499-517	NULL
.	NULL

Smith	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
R.	NULL
Petty	NULL
,	NULL
P.	NULL
Parham	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
McConnell	NULL
.	NULL

1982	NULL
.	NULL

Cell	NULL
surface	NULL
properties	NULL
of	NULL
HLA	NULL
antigens	NULL
in	NULL
Epstein-Barr	NULL
virus-transformed	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
79:608-612	NULL
.	NULL

Spits	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Borst	NULL
,	NULL
M.	NULL
Giphart	NULL
,	NULL
J.	NULL
Cougan	NULL
,	NULL
C.	NULL
Terhorst	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
De	NULL
Vries	NULL
.	NULL

1984	NULL
.	NULL

HLA-DC	NULL
antigens	NULL
can	NULL
serve	NULL
as	NULL
recognition	NULL
elements	NULL
for	NULL
human	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

14:299-304	NULL
.	NULL

Spruance	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
S.	NULL
Chow	NULL
.	NULL

1980	NULL
.	NULL

Pathogenesis	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
in	NULL
cultures	NULL
of	NULL
epidermal	NULL
cells	NULL
from	NULL
subjects	NULL
with	NULL
frequent	NULL
recurrences	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

142:671-675	NULL
.	NULL

Tigges	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
S.	NULL
Leng	NULL
,	NULL
D.	NULL
C.	NULL
Johnson	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Burke	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
herpes	NULL
simplex	NULL
(	NULL
HSV	NULL
)	NULL
-specific	NULL
CD8+	NULL
CTL	NULL
clones	NULL
recognize	NULL
HSV-2	NULL
infected	NULL
fibro-blasts	NULL
after	NULL
treatment	NULL
with	NULL
IFN-gamma	NULL
or	NULL
when	NULL
virion	NULL
host	NULL
shutoff	NULL
functions	NULL
are	NULL
disabled	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:3901-3910	NULL
.	NULL

Torseth	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
G.	NULL
H.	NULL
Cohen	NULL
,	NULL
R.	NULL
J.	NULL
Eisenberg	NULL
,	NULL
P.	NULL
W.	NULL
Berman	NULL
,	NULL
L.	NULL
A.	NULL
Lasky	NULL
,	NULL
C.	NULL
P.	NULL
Cerini	NULL
,	NULL
C.	NULL
J.	NULL
Heilman	NULL
,	NULL
S.	NULL
Kerwar	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Merigan	NULL
.	NULL

1987	NULL
.	NULL

Native	NULL
and	NULL
recombinant	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
envelope	NULL
proteins	NULL
induce	NULL
human	NULL
immune	NULL
T-lymphocyte	NULL
responses	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1532-1539	NULL
.	NULL

Watson	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
R.	NULL
DeMars	NULL
,	NULL
I.	NULL
S.	NULL
Trowbridge	NULL
,	NULL
and	NULL
F.	NULL
H.	NULL
Bach	NULL
.	NULL

1983	NULL
.	NULL

Detection	NULL
of	NULL
a	NULL
novel	NULL
human	NULL
class	NULL
II	NULL
HLA	NULL
antigen	NULL
.	NULL

Nature	NULL
304:358-360	NULL
.	NULL

Whitley	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

1996	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
,	NULL
p.	NULL
2297-2342	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

,	NULL
vol	NULL
.	NULL

2	NULL
.	NULL

Lippincott-Raven	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Williams	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Parris	NULL
.	NULL

1987	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
deoxyuridine	NULL
triphosphate	NULL
nucleotidohydrolase	NULL
and	NULL
mapping	NULL
of	NULL
a	NULL
gene	NULL
conferring	NULL
type	NULL
specificity	NULL
for	NULL
the	NULL
enzyme	NULL
.	NULL

Virology	NULL
156:282-292	NULL
.	NULL

Wohlrab	NULL
,	NULL
F.	NULL
,	NULL
B.	NULL
K.	NULL
Garrett	NULL
,	NULL
and	NULL
B.	NULL
Francke	NULL
.	NULL

1982	NULL
.	NULL

Control	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus-induced	NULL
deoxypyrimidine	NULL
triphosphatase	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
mutants	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
types	NULL
1	NULL
and	NULL
2	NULL
and	NULL
intertypic	NULL
recombinants	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

43:935-942	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Inatsuki	NULL
,	NULL
T.	NULL
Horiuchi	NULL
,	NULL
and	NULL
Y.	NULL
Kobayashi	NULL
.	NULL

1991	NULL
.	NULL

Functional	NULL
heterogeneity	NULL
among	NULL
herpes	NULL
simplex	NULL
virus-specific	NULL
human	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:1341-1347	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Zarling	NULL
.	NULL

1984	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
43.	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus-infected	NULL
cells	NULL
.	NULL

II	NULL
.	NULL

Bifunctional	NULL
clones	NULL
with	NULL
cytotoxic	NULL
and	NULL
virus	NULL
induced	NULL
proliferative	NULL
activities	NULL
exhibit	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
type	NULL
2	NULL
specific	NULL
,	NULL
or	NULL
type	NULL
common	NULL
reactivities	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

133:2736-2742	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Zarling	NULL
.	NULL

1985	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus-infected	NULL
cells	NULL
.	NULL

III	NULL
.	NULL

Analysis	NULL
of	NULL
viral	NULL
glycoproteins	NULL
recognized	NULL
by	NULL
CTL	NULL
clones	NULL
by	NULL
using	NULL
recombinant	NULL
herpes	NULL
simplex	NULL
viruses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134:2679-2687	NULL
.	NULL

CD4	NULL
T	NULL
CELLS	NULL
SPECIFIC	NULL
FOR	NULL
HSV-2	NULL
TEGUMENT	NULL
PROTEINS	NULL
44	NULL
.	NULL

45	NULL
.	NULL

7483	NULL
Zarling	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
A.	NULL
Moran	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
C.	NULL
Pach	NULL
]	NULL
,	NULL
P.	NULL
W.	NULL
Berman	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Lasky	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus-infected	NULL
cells	NULL
.	NULL

IV	NULL
.	NULL

Recognition	NULL
and	NULL
activation	NULL
by	NULL
cloned	NULL
glycoproteins	NULL
gB	NULL
and	NULL
gD-1	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:4669-4673	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
C.	NULL
McKnight	NULL
.	NULL

1993	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
U	NULL
;	NULL
46	NULL
and	NULL
U	NULL
;	NULL
47	NULL
deletion	NULL
mutants	NULL
lack	NULL
VP11	NULL
and	NULL
VP12	NULL
or	NULL
VP13	NULL
and	NULL
VP14	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
exhibit	NULL
altered	NULL
thymidine	NULL
kinase	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1482-1492	NULL
.	NULL

